Effectiveness of Highly Active Antiretroviral Therapy in HIV patients in resource-limited settings by Tuboi, Suely Hiromi
EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV 
PATIENTS IN RESOURCE-LIMITED SETTINGS 
 
 
 
 
 
 
 
 
by 
 
Suely Hiromi Tuboi 
 
MD, Universidade Estadual de Londrina, Brazil, 1991 
 
MSc, Universidade Estadual de Campinas, Brazil, 2001 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
 
Graduate School of Public Health in partial fulfillment of 
 
the requirements for the degree of  
 
Doctor of Philosophy 
 
 
 
 
 
 
 
University of Pittsburgh 
 
2008 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
This dissertation was presented 
by 
Suely Hiromi Tuboi 
It was defended on 
February 01, 2008 
and approved by 
 
Roslyn Stone, PhD 
Associate Professor 
Department of Biostatistics, Graduate School of Public Health 
University of Pittsburgh 
Leland Yee, PhD 
Assistant Professor 
Department of Epidemiology, Graduate School of Public Health 
Department of Medicine, School of Medicine 
University of Pittsburgh 
Deborah McMahon, MD  
Associate Professor 
Department of Medicine, School of Medicine 
University of Pittsburgh 
Lawrence Kingsley, DrPH., MPH 
Associate Professor 
Departments of Epidemiology and Infectious Diseases and Microbiology 
Graduate School of Public Health 
University of Pittsburgh 
Dissertation Director: Lee H. Harrison, MD 
Professor 
Department of Medicine, School of Medicine 
Departments of Epidemiology and Infectious Diseases and Microbiology 
Graduate School of Public Health  
University of Pittsburgh 
 ii
  
 
 
  
 
 
 
 
 
 
Copyright © by Suely Hiromi Tuboi 
2008 
 iii
Lee H. Harrison, MD 
 
EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV PATIENTS 
IN RESOURCE-LIMITED SETTINGS 
Suely Hiromi Tuboi, PhD 
University of Pittsburgh, 2008 
 
The HIV pandemic has posed an unprecedented challenge to the global health, devastating 
communities and reinforcing the historical problems that link ill-health with poverty. Sound 
evidence for public health decision-making is needed as antiretroviral programmes are being 
rolled out in developing countries. This thesis discusses the effectiveness of Highly Active 
Antiretroviral Therapy (HAART) in resource-limited countries from the Antiretroviral Therapy 
in Lower Income Countries (ART-LINC), a network of HIV/AIDS treatment programmes and 
cohorts in Africa, South America, and Asia. The objectives of this project were to document the 
effectiveness of HAART in these settings, defined by changes in immunologic and virologic 
markers within 6 months of treatment; assess factors associated with 6-month response to 
therapy; and to assess the association of 6 month response with long-term outcomes. 
In the first article, the evidence supporting effectiveness of HAART is reviewed, focusing 
on aspects of immunologic and virologic responses to therapy. Despite the lack of a standardized 
definition of immunologic and virologic response, we conclude that around one third of the 
patients who start HAART show a response pattern where either immunologic or virologic 
response is not achieved, a condition referred to as discordant response.  
The second and third articles provide a picture of the association between HAART and 6-
month response in resource-limited countries. Overall, the effectiveness of HAART in these 
settings is similar to that reported in resource-rich countries. Finally, we assessed the association 
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between immunologic and virologic discordant responses at 6 months and mortality in ART-
LINC. We found that the hazard of death for those showing discordance at 6 months was similar 
to that reported in resource-rich countries. However, we found that early mortality was high in 
Africa and Asia, and a significant proportion of patients that did not have access to laboratory 
measurements were also at greater risk of death. This is the first report on the association of 
discordant responses and mortality in lower income countries, which provides important 
evidence for public health decision making in the context of antiretroviral rollout. 
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1.1 EFFICACY AND EFFECTIVENESS OF HAART IN DEVELOPED COUNTRIES 
In industrialized countries, the widespread use of highly active antiretroviral therapy (HAART) 
has led to major reductions in morbidity and mortality associated with HIV infection [1-6]. The 
initiation of HAART rapidly and significantly reduces the levels of virus replication in the 
peripheral blood, and increases levels of CD4 count [7, 8], two important predictors of disease 
progression.  
In randomized controlled trials, HAART was shown to reduce plasma viral load (PVL) to 
less than 500 copies/Ml in 60 to 90% of the patients [5-8]. A meta-analysis of 23 clinical trials 
involving 31 independent treatment groups, 19 unique antiretroviral regimens, and 3,257 
enrolled treatment naïve patients, showed that 64% (95% Confidence Interval [CI] 60 – 67) of 
patients taking HAART showed viral suppression (PVL<400 copies/Ml) at 24 weeks [9].  
Observational studies, which better reflect the clinical practice, have shown a variety of 
results, using different thresholds and timeframes to define virologic response. Table 1 shows 
virologic response in several observational studies reported in the literature. 
 
Table 1. Virologic response in various observational studies from developed countries 
Author N Study Population Definition of virologic 
success (log10 or copies/mL) 
Virologic success 
rate (%) 
Mocroft et 
al.[10] 
243 PI naïve, including pre-
treated patients 
PVL<400 copies at 6 months 52.8 
Lucas et al. [11]  273 PI naive, including pre-
treated patients 
PVL<500 copies at 1–90 
days, and 3–7 and 7–14 
months 
42.0 at 1–90 days; 
44.0 at 3–7 
months; and 37.0 at 
7–14 months 
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Table 1 continued: 
 
Author N Study Population Definition of virologic 
success (log10 or copies/mL) 
Virologic success 
rate (%) 
Ledergerber et 
al. [12] 
2674 Pre-treated and naive patients PVL<400 copies by 12 
months 
90.7 of treatment 
naive and 70.3–
78.7 of pre-treated 
Staszewski et al. 
[13] 
901 PI naive, including pre-
treated patients 
PVL<500 copies at 6 months 79.0 
Paredes et al. 
[14] 
1469 HAART naïve, including pre-
treated patients 
PVL<500 copies at 6 months 60.4 
Grabar et al. [15] 1402 PI naive, mostly (>80%) pre-
treated patients 
PVL<1000 copies at 12 
months 
50.0 
Le Moing et al. 
[16] 
1129 PI naive, including pre-
treated patients 
PVL<500 copies at 4 months 73.5 
Pulido et al. [17] 310 HAART naïve, severely 
immunodepressed patients 
(CD4 cell count<100) 
PVL<400 copies at 6 months Efavirenz 
recipients: 74.4; 
PIs recipients: 57.8 
PI: Protease Inhibitor 
PVL: Plasma Viral Load 
 
More important, studies have shown that early patterns of change in both virologic and 
immunologic responses to HAART predict progression to AIDS or death, independent of pre-
treatment clinical or laboratory parameters. For example, among 1,132 HIV-infected women 
from the Women’s Interagency HIV Study (WIHS), Anastos et al. found that CD4+ cell count 
and PVL attained after treatment initiation were stronger predictors of clinical progression and 
death than pre-treatment values [18]. Another study of 2,236 HIV patients who started on 
HAART with 1 PI in France found that patients showing a virologic only response at 6 months 
were at higher risk of clinical progression or death than those showing a complete response [15]. 
Several studies, using different definitions, have documented the frequency, risk factors and 
long-term outcomes associated with discordant responses in developed countries. 
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 1.2 ARTICLE 1 – DISCORDANT IMMUNOLOGIC AND VIROLOGIC RESPONSES 
TO ANTIRETROVIRAL THERAPY 
(From manuscript originally published in the Journal of Antimicrobial Chemotherapy 58: 506 -10, 
2006) 
 
Mauro Schechter1 and Suely Hiromi Tuboi2
 
1Infectious Diseases Service, Hospital Universitário Clementino Fraga Filho; Department of 
Preventive Medicine, Universidade Federal do Rio de Janeiro 
 
 2Infectious Diseases Epidemiology Research Unit, Graduate School of Public Health and School 
of Medicine, University of Pittsburgh. 
 
 
 
 
 
 
 
 
 
 
 
Key words: CD4 lymphocyte count; viral load; treatment outcome 
 5
1.2.1 ABSTRACT 
 
In response to antiretroviral therapy, some patients experience what has been termed a discordant 
response, characterized either by a sustained CD4+ cell count rise despite persistent viraemia or 
by HIV-1 RNA plasma levels below the limit of detection accompanied by a blunted CD4+ cell 
count response. In part because of a lack of universally accepted definitions, published estimates 
of the frequency of discordant responses vary considerably. Little is known about the 
pathogenesis of discordant responses, which seems to depend on the interaction of a multitude of 
viral, host, and treatment-related factors. Available evidence indicates that discordant responses 
are associated with an intermediate risk of death or clinical progression. At present, 
recommendations for the clinical management of patients with discordant responses to 
antiretroviral therapy are largely based on observational, uncontrolled data. The development of 
standardized and universally accepted definitions of discordant responses is necessary to allow 
meaningful comparisons between studies to be made, as well as to help in the design trials of 
possible therapeutic interventions. 
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1.2.2 INTRODUCTION 
The introduction of highly active antiretroviral therapy (HAART) into clinical practice has led to 
dramatic reductions in morbidity and in mortality associated with infection with the human 
immunodeficiency virus (HIV). The initiation of HAART generally leads to a rapid reduction in 
HIV-1 RNA plasma levels and to an increase in peripheral CD4+ cell counts[5, 7, 8]. However, 
some patients experience a “discordant response”, whereby the HIV-1 RNA plasma level is 
below the limit of detection but the CD4+ cell count response is blunted. Other patients exhibit a 
different pattern of discordant response, characterized by a sustained CD4+ cell count response, 
despite persistent viraemia. In this article, we discuss the epidemiology, risk factors, prognosis, 
and recommendations for the clinical management of patients with discordant responses.  
 
1.2.3 EPIDEMIOLOGY 
It is not surprising that, given the lack of universally accepted definitions of virologic and 
immunologic success, published estimates of the frequency of discordant responses vary 
considerably (Table 2). Definitions of virologic success that have been used include HIV-1 RNA 
plasma levels below 50, 400 or 1,000 copies/mL, whereas definitions of immunologic response 
include increases in CD4+ cells counts above a certain value (usually 50 cells at the end of the 
first year of therapy) or maintenance of CD4+ cell counts above a certain threshold (generally 
200 cells/mm3).  
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Table 2. Discordant responses in various observational studies 
Proportion of discordant 
responses (%) 
Author N Study Population Definition of immunologic 
(cells/mm3) and of virologic 
responses (log10 or copies/mL) 
Virologic 
only 
Immunologic 
only 
Piketty et al.  162 PI naïve, previously NRTI 
experienced 
↑ CD4+>50 and ↓ PVL>1 log10 
over mean follow-up of 12.1 months 
10.5 10.5 
Grabar et al.  2,236 PI naïve, including pre-
treated patients 
↑ CD4+>50 and ↓ PVL>1 log10 at 6 
months  
17.3 19.0 
Nicastri et al.  2,143 PI naïve, including pre-
treated patients 
↑ CD4+>100 and PVL<500 at 12 
months  
15.7 20.6 
Mehta et al.  265 Injecting drug users 
initiating HAART, including 
pre-treated patients 
↑ CD4+>50 or CD4+>500 and 
PVL<1,000 at 12 months 
16.0 21.0 
Moore et al.  2,217 Previously treatment naïve 
patients initiating HAART 
↑ CD4+>50 and PVL<500 at 6 
months 
15.4 11.7 
Marimoutou 
et al.  
478 Patients initiating HAART 
with PI, including pre-
treated patients 
↑ CD4+>50 and PVL<500 at 6 
months 
15.7 23.8 
Schechter et 
al.  
1,916 Previously treatment naïve 
patients initiating HAART 
↑ CD4+>50 and PVL<500 at 6 
months 
14.0 19.0 
 
 
In industrialized countries, discordant responses have been reported to occur in 20 to 30% of 
patients 6 months to 2 years after starting therapy. For example, in a cohort of 162 HIV patients 
receiving indinavir and followed for a median of 10.5 months, Piketty et al. found equal rates 
(10.5%) of immunologic only, and virologic only responses. The authors defined immunologic 
success as an increase of 50 CD4+ cells/mm3 and virologic success as either a decrease in HIV 
RNA plasma viral load by 1 log10 or achieving a plasma viral load < 400 copies/mL at any point 
during the follow-up period (median 12 months, range 2 to 15 months) [19]. In another study, 
conducted in France, immunologic success was defined as an increase of CD4+ > of more than 
50 cells/mm3 and virologic success as a decrease in HIV RNA viral load of more than 1 log10 
copies/mL, after 6 months on treatment. In 2,236 protease inhibitor (PI) naïve patients studied 
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19% exhibited immunologic only response, whereas 17.3% had virologic only response[15]. In a 
study conducted in Italy, which included 3,094 anti-retroviral naïve and experienced patients, 
20.6% were reported to have immunologic only responses and 15.7% to have virology only 
response. The definitions used in this study were an increase of at least 100 CD4+ cells/mm3 and 
plasma viral load levels below 500 copies/mL at 12 months[20]. In a cohort of 265 injecting drug 
users (IDU) in Baltimore, Maryland, immunologic and virologic only responses were observed 
in 21 and 16%, respectively. Virologic response was defined as a viral load < 1,000 copies/mL 
and immunologic response as either an increase of 50 CD4+ cells or achieving CD4+ >500 
cells/mm3 at the end of the first year on HAART[21]. In a study conducted in British Columbia, 
Canada, an increase in 50 CD4+ cells/μL and achieving viral load<500 copies/mL at 6 months 
on therapy were used to define successful immunologic and virologic responses, respectively. 
The study involved 1,527 treatment-naive patients and found that 11.7% and 15.4% of the 
subjects showed immunologic and virologic only responses, respectively[22].  
There are limited data on discordant responses in patients being treated in developing 
countries. The Antiretroviral Therapy in Lower Income Countries Collaboration (ART-LINC), 
an epidemiologic network of HIV/AIDS treatment programs in Africa, Asia, and South America, 
has reported on the frequency of discordant responses in 1,916 previously treatment-naïve 
patients seen in 15 developing countries who initiated HAART between March 1996 and April 
2004. 269 (14%) were virologic only and 365 (19%) were immunologic only responders [23] 
with virologic response defined as achieving a plasma HIV RNA viral load < 500 copies/mL, 
and immunologic response defined as an increase of at least 50 CD4 cells/mm3 at 6 months.  
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1.2.4 RISK FACTORS 
Little is known about the pathogenesis of discordant responses, which seems to depend on the 
interaction of a multitude of viral, host, and treatment-related factors.  
A blunted CD4 response despite suppression of viral replication has often been attributed to 
host characteristics, particularly older age[15, 22, 24-26]. It has been hypothesized that the 
magnitude of immune restoration is dependent on thymus activity, which decreases with age[27]. 
Poor CD4 cell reconstitution despite virologic response has also been correlated with a lower 
nadir pre-treatment CD4+ cell count, suggestive of more extensive depletion of CD4+ cells in 
the gut-associated lymphoid tissue during primary (acute) HIV infection, which may be slow or 
refractory to reconstitution with antiretroviral therapy[28, 29]. Moreover, it has been suggested 
that the rate of CD4+ cell depletion after HIV infection is established is also important: slower 
rates of decrease in CD4+ cell counts before therapy initiation are associated with a slower early 
recovery, whereas sharper slopes of CD4+ cell decrease with maximal subsequent cell 
distribution once therapy is instituted[30].  
Genetic variability has also been investigated as a possible modulator of immunologic 
recovery. An example is the multidrug-resistance transporter gene MDR1, which codes for P-
glycoprotein, an essential protein involved in transportation of many different substrates, 
including antiretroviral drugs. Overexpression of P-glycoprotein lowers intracellular 
concentration of protease inhibitors[31] and could therefore affect reconstitution of CD4+ cell 
pool. Association of MDR1 polymorphism (3435 TT genotype) with improved CD4 recovery 
was found in two studies,[32, 33] but not in another[34]. Polymorphisms within the CCR5 gene, 
which codes for a key cell surface co-receptor for macrophage-tropic strains of HIV-1, have long 
been associated with different patterns of susceptibility to infection [35] and disease progression 
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[36]. However, it appears that such polymorphisms do not have a significant impact on initial 
virological and immunological response to antiretroviral therapy [37, 38]. Finally, a few studies 
have looked at genes that are associated with T lymphocyte apoptosis. Combination of some 
polymorphisms of Fas and Fas ligand (FasL), two important genes that control T lymphocyte 
homeostasis [39], and carriage of a specific allele that encodes IL-6 production [38] have been 
implicated on altered CD4+ recovery.  
Other factors that have been reported associated with blunted CD4+ response are infection 
by HIV-2[40], co-infection by HTLV-1 (human T-lymphotropic virus type I), or HTLV-2, and 
due to drug toxicity. The use of the combination tenofovir + didanosine [41, 42] has been 
implicated in failure to increase CD4+ cell count despite of viral suppression, and this effect is 
apparently dependent on doses of didanosine. The underlying mechanism is thought to be a 
synergistic effect of both tenofovir and didanosine metabolites in producing an imbalance in the 
purine pool within CD4+ T lymphocytes, which, in turn, has a cytostatic effect on these cells 
[43].  
The use of zidovudine or didanosine, as part of the antiretroviral regimen, both which can 
cause lymphopenia, the concurrent use of other myelotoxic drugs such as co-trimoxazole, or the 
presence of certain co-infections, such as HTLV-1, have all been associated with sub-optimal 
CD4+ cell responses despite suppression of viral replication.  
The physiology of a good immunologic response in the presence of virologic failure is also 
not well understood and possibly involves various aspects of virus-drug-host dynamics. In one 
closely followed cohort of 402 patients who had laboratory evaluations repeatedly in the first 
year after initiation of HAART, all but 2 of the 25 immunologic only responders had either a 
prior transient period of undetectable plasma viraemia or, at least, HIV-1 RNA plasma levels 
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below <1000 copies/mL suggesting that temporary or partial viral suppression was the primary 
mechanism involved in the observed increases in CD4+ cell counts [44]. One possible 
explanation is that HAART selects for viral strains with lower replicative capacity and reduced 
pathogenicity. The observation that virus isolated from recipients of protease inhibitor (PI)-based 
regimens with stable CD4+ cell counts despite virologic failures have decreased viral replication 
capacity seems to corroborate this hypothesis[45, 46]. In one study, lower replication capacity, or 
reduced fitness, was associated with the presence of non-syncytium-inducing viral phenotype, 
decreased cellular activation, and enhanced interferon-γ production in response to gag and tat 
antigens in the setting of extensive genotypic and phenotypic resistance to PIs [46]. Patients in 
this study exhibited sustained or even increased CD4+ counts for periods exceeding 5 years 
without disease progression, despite extensive and stable antiretroviral resistance profile[47]. 
The sustained increase in CD4+ cell count in the context of prolonged virologic failure may be 
explained by a state of relative immunologic quiescence, in which T cell dynamics are similar 
but not identical to what occurs in complete responders, in which the turnover of CD4+ cells has 
been shown to be slower, denoted by their reduced expression of markers of activation (CD38+, 
HLA-DR+) and active cycling (Ki67+), compared to untreated patients [48].  
Antiretroviral resistance mutations that are associated with reduced replication capacity have 
been frequently reported in patients with immunologic response despite virologic failure. 
Although both immunologic only responders and non-responders seem to share a similar 
resistance pattern, a higher percentage of viral strains carrying the M184V mutation, associated 
with lamivudine resistance, has been reported in immunologic only responders than in non-
responders [49-51]. In one study of patients who remained on a stable PI-based regimen despite 
detectable plasma viraemia, the emergence of primary mutations V82A, I84V and/or L90M were 
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associated with a decreased replicative capacity [52]. In another study in patients who had failed 
HAART, the M36I mutation was only found in immunologic only responders [51].  
There are no published controlled studies evaluating the impact of different antiretroviral 
regimens on the incidence of discordant responses. On the other hand, published observational 
studies mostly include patients receiving PI-based regimens. In the observational study of Moore 
et al, no association was found between type of regimen and presence of discordant responses 3 
to 9 months after HAART initiation [22]. Nonetheless, there are data to indicate that the degree 
of impairment in viral replicative capacity in virus isolated from patients with discordant 
responses may depend on the type of antiretroviral regimen being used, replicative capacity 
being higher in patients on non-nucleoside reverse transcriptase inhibitor-based regimens than in 
patients receiving PI- based regimens, perhaps reflecting different barriers to selection of 
resistant virus [53]. There are also data to indicate that in patients with sustained CD4+ cell 
counts despite prolonged virologic failure, interruption of the PI while maintaining the reverse 
transcriptase inhibitor backbone had little impact on CD+ cell counts or plasma viraemia, 
whereas the reverse led to significant increases in HIV-1 RNA plasma levels and decreases in 
CD4+ cell counts [48].  
Adherence to therapy may also influence the occurrence of discordant responses. In the 
study of Moore et al, sub-optimal adherence was found to be associated both with virologic and 
immunologic only responses [22].  
  
1.2.5 PROGNOSIS 
The use of different definitions of virologic and immunologic responses, as well as different 
follow-up periods, do not allow for direct comparisons between the various studies that 
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attempted to determine the prognostic impact of discordant responses. Nonetheless, the majority 
of published studies have indicated that, in comparison to complete response, discordant 
responses are associated with an intermediate risk of death or clinical progression.  
In the previously cited study of Grabar et al., virologic only responders and non-responders 
had a higher probability of clinical progression, whereas immunologic only and complete 
responders had similar risks [15]. In contrast, in other studies immunologic only response was 
also associated with a higher risk of clinical progression. In one cohort of antiretroviral 
experienced patients with advanced HIV disease starting PI based HAART, who were followed 
for over 30 months, discordant responders at 12 months experienced significantly more AIDS-
defining events than complete responders, with immunologic only responders presenting a 
slightly higher probability of being event-free compared to virologic only responders [25]. In 
another study involving over 2,100 antiretroviral experienced and naïve HIV patients followed 
for a median of 44 months, immunologic only and virologic only responders had a significantly 
lower risk of clinical progression than non-responders, but a 2.3 and 1.9-fold greater risk of death 
or of experiencing a new AIDS-defining event than complete responders, respectively [15].  
Very few studies have assessed the prognostic impact of discordant responses in naïve 
patients and in recipients of NNRTI-base regimens. In the study of Moore et al., mortality was 
increased in patients showing an early discordant response, but no statistically significant 
difference was found between immunologic and virologic only responders [22]. Likewise, in a 
study involving HAART naïve IDU patients, discordant responders had an increased mortality 
compared to complete responders, but progression rates did not differ by whether early response 
was immunologic or virologic only [21]. We are not aware of any published study assessing the 
prognostic impact of discordant responses in low-income settings. 
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1.2.6 CLINICAL MANAGEMENT 
At present, recommendations for the clinical management of patients with discordant responses 
to antiretroviral therapy are largely based on observational, uncontrolled data. For patients on a 
new regimen, who after several months of treatment the HIV-1 RNA level is below the limit of 
detection but the CD4+ cell count response is blunted, it is recommended to maintain the current 
regimen. Changing or intensifying the regimen has not been shown to have an effect on the 
CD4+ cell count response, except in the case of patients whose regimen contains antiretroviral 
drugs that are associated with lymphopenia, such as zidovudine or didanosine. One controlled 
study showed that concomitant administration of human recombinant growth hormone may be 
beneficial in enhancing immunologic response chronically infected patients [54]. If the patient is 
using concomitant medications associated with bone marrow toxicity, their interruption or 
substitution should be judiciously considered. 
Given that no benefit has so far been demonstrated and the potential for significant toxicity, 
the use of immune modulators, such as interleukin-2, is not recommended, except in the setting 
of clinical trials. For patients with a sustained CD4+ cell count response, despite persistent 
viraemia, the goal of therapy should remain the suppression of HIV-1 RNA to levels below 50 
copies/mL. A detailed assessment of adherence, drug intolerance and pharmacokinetic issues 
should be done to rule out modifiable causes. If none is encountered, then modifications in the 
antiretroviral regimen should be considered, the choice of drugs being dependent upon patient 
history and resistance testing. For patients who have previously failed multiple regimens, it may 
not be feasible to achieve plasma HIV-1 RNA levels of less than 50 copies/mL. For these 
patients, stability of CD4+ cell counts becomes the objective of treatment.  
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1.2.7 CONCLUSIONS  
There are limited information on the pathogenesis, risk factors, prognosis and clinical 
management of discordant immunologic and virologic responses to antiretroviral therapy, despite 
its relative frequency. The development of standardized and universally accepted definitions of 
discordant responses is necessary to allow meaningful comparisons between studies to be made, 
as well as to help in the design trials of possible therapeutic interventions.  
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1.3 EFFECTIVENESS OF HAART IN RESOURCE-LIMITED SETTINGS 
Although well documented in high income countries, data on response to therapy in resource-
limited countries are limited. According to the 2007 report on the scaling up antiretroviral 
therapy strategy by the World Health Organization (WHO), in 2006, almost 700,000 people 
received treatment for the first time, and by December 2006 it was estimated that 2,015,000 
(1.8−2.2 million) people living with HIV/AIDS were receiving treatment in low- and middle-
income countries, representing 28% (24%−34%) of the estimated 7.1 million (6.0−8.4 million) 
[55]. The urgent need for quickly scaling up HAART has posed a complex challenge to the 
design and assessment of public health interventions as controlled trials cannot be used in such 
circumstances for ethical reasons. Evidence base, however, is necessary to demonstrate effect, 
assure a rational utilization of, and secure future funding of such interventions. 
Data from observational studies suggest that virological and immunological efficacy of 
HAART appears to be as good as that observed in developed countries [56-58]. In a meta-
analysis of 10 observational studies, HIV RNA viral load suppression was found in 
approximately 60-70% of individuals at time points up to month 18 [57].  
With the rollout of HAART in developing countries, a high priority has been put into 
conduct research on its operational aspects, in particular to identify appropriate models of care 
and support to increase effective coverage in the long term [59-61]. It is also important that this 
research be timely and rooted in routine clinical management, and designed as multi-country 
studies that purposefully select countries with different relevant contextual factors, using 
hierarchical models to investigate the role of variables at each level [61].  
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1.3.1 The ART-LINC Collaboration 
The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, a network 
of HIV/AIDS treatment programmes and cohorts in Africa, South America, and Asia was set up 
in 2003 to address these questions. The three primary objectives of ART-LINC are (i) to define 
the prognosis of HIV-1 infected patients treated with HAART in resource-limited settings; (ii) to 
compare the experience between different settings, delivery modes and types of monitoring; and 
(iii) to compare prognosis in resource-limited settings with that observed in industrialized 
nations. Importantly, both individual and programme level characteristics are of interest in this 
context. The current database includes patients from 15 countries from 3 continents: 3 countries 
North and Western Africa (Morocco, Côte d’Ivoire, and Senegal); 3 from Central and Eastern 
Africa (Kenya, Uganda, and Rwanda); 5 from Southern Africa (Botswana, Malawi, South 
Africa, Zambia, and Zimbabwe); 2 from South America (Argentina and Brazil), and 2 from Asia 
(India and Thailand) [62]. 
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1.4 SPECIFIC AIMS 
We here present 3 specific aims that address important aspects of HAART effectiveness in 
middle- and low-income countries, utilizing data from the ARTLINC collaboration.  
 
Specific aim 1: to describe the virologic response in previously naïve patients starting HAART 
in a cohort of HIV infected patients in Porto Alegre, Brazil, and assesses risk factors for 
virologic failure at 6 months.  
Specific aim 2: to assess the frequency of and risk factors for immunovirologic discordant 
responses in the ART-LINC collaboration.  
Specific aim 3: to assess the long-term effect of early immunovirologic discordant responses on 
mortality in the ART-LINC collaboration. 
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2.1 ABSTRACT 
Objective: To assess predictors of virological response 6 months after initiation of highly active 
antiretroviral therapy (HAART) in a cohort of HIV infected patients in Brazil. 
Methods: Treatment naïve patients who started HAART between 1996 and 2004 and had 
information on viral load at 3-9 months were included. Information was collected on 
demographic characteristics, antiretroviral regimen, adherence, AIDS diagnosis, baseline CD4 
cell count, and viral load. Virological failure (VF) was defined as viral load >400 copies/mL at 6 
months or death before completion of 6 months of therapy.  
Results: Among 454 patients who met the inclusion criteria, VF occurred in 127 (28.0%). In 
univariate analysis, VF was associated with younger age [median 34 vs. 37, p<0.01], AIDS 
diagnosis (RR 1.18, p<0.01), higher baseline viral load [5.34 vs. 5.00, p<0.01], lower baseline 
CD4 cell count [86 vs. 182, p<0.01], non-adherence (RR 1.39, p<0.01), regimen containing 1 
single protease inhibitor, as compared to ritonavir boosted regimens (OR 8.5, p<0.01), and year 
therapy initiated before 1999 (p<0.01). To minimize the systematic effect of therapy indication, 
we analyzed the subset of 158 patients with CD4 count <200 cells/uL who started therapy after 
1999. After adjusting for age, education, adherence, regimen and baseline viral load, non-
adherence (OR 8.78, p=0.02) and fewer years of education (OR 6.05, p=0.05) remained 
associated with VF.  
Conclusions: We found a significant improvement in virological suppression over time, 
consistent with the introduction of non-nucleoside reverse transcriptase inhibitors and ritonavir 
boosted regimens into clinical practice. With currently available therapies, compliance and 
education were shown to be predictors of virological response, particularly in more 
immunocompromised patients.  
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2.2 INTRODUCTION 
In developed countries, the widespread use of highly active antiretroviral therapy (HAART) has 
led to major reductions in morbidity and mortality associated with HIV infection [1, 2, 6, 7, 63]. 
In Brazil, since 1996 access to antiretroviral therapy has been universal and free of charge to all 
individuals who qualify for treatment according to national guidelines. Nonetheless, data on the 
response to HAART in Brazil are limited [64-68].  
Studies conducted in developed countries have indicated that in therapy-naïve patients, 
virological response at 6 months of HAART is an important independent predictor of 
progression to AIDS or death, independent of pre-treatment clinical or laboratory parameters [15, 
18, 69].  
In the present study, we evaluated response to therapy in a cohort of treatment naïve HIV 
infected patients who started HAART between 1996 and 2004 in a public outpatient HIV clinic 
in Porto Alegre, Brazil.  
2.3 METHODS 
2.3.1 Study design and patients 
This retrospective cohort study included all treatment-naïve, HIV-infected adults who attended 
the HIV/AIDS outpatient clinic at the Hospital de Clínicas de Porto Alegre, were prescribed 
HAART between January 1996 and January 2004, and for whom information was available on 
HIV PVL 3-9 months after treatment was initiated. This clinic is a government-owned facility 
where antiretroviral drugs and treatment are provided free-of-charge, and is a participating site in 
the ART-LINC collaboration. 
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To adjust for changes in clinical practices over time and for differences due to selection-by-
indication bias, we performed two additional analyses: Stratification by year of therapy initiation 
(from 1996 to 1998 and after 1999, the year NNRTIs became available in Brazil); and, an 
analysis that included only the subgroup of patients with baseline CD4 cell counts less than 
200/uL and who started therapy after 1999.  
2.3.2 Study variables and outcomes 
Demographic variables that were analyzed included: sex, age, risk behavior, race and education 
in years. HAART was defined as any combination of three or more antiretroviral drugs including 
two nucleoside reverse-transcriptase inhibitors (NRTI) and at least one protease inhibitor (PI) or, 
one nonnucleoside reverse-transcriptase inhibitor (NNRTI). Antiretroviral regimens were 
categorized into three major groups: PI (regimens containing two NRTI and one PI); NNRTI 
(regimens containing two NRTI and one NNRTI), ritonavir-boosted containing regimens 
(regimens containing two NRTI, low dose ritonavir, and at least one more PI). Patients started on 
regimens containing only NRTIs (two NRTI and abacavir) were excluded from the analysis 
because of their limited number.  
Baseline CD4 counts and HIV plasma viral load were those measured up to 3 months before 
the start of therapy. Virological failure was defined as a HIV PVL greater than or equal to 400 
copies/μL 3 to 9 months (closest to 6 months) after treatment initiation. When more than one 
measurement was available, the one closest in time to 6 months of therapy was selected. Non-
adherence to therapy was self-reported, and was defined as having missed one or more doses in 
the week before the clinic visit. The 1993 revised CDC AIDS case definition was used [70].  
 23
2.3.3 Statistical analysis 
An intent-to-continue-treatment approach, which ignored subsequent therapy changes or 
interruptions, was used. Univariate analyses were performed by using Chi Square or Fisher’s 
exact test for categorical variables, and Student t test or Wilcoxon test for continuous variables. 
Relative risks or odds ratios and 95% CI were also determined. HIV plasma viral load and CD4 
cell count were normalized using log10 and square root transformations, respectively. For 
multiple comparisons, we used the ANOVA procedure and comparisons between groups were 
adjusted for type I error using the Bonferroni correction. Variables with p<0.10 in the univariate 
analysis were included in the multivariate analyses. We used a stepwise approach to assess 
factors independently associated with outcome. All p values are two sided. SAS version 8.0 
(SAS Institute, Cary, NC) was used for all analyses. 
2.4 RESULTS 
From 1996 to 2003, 1,976 patients started HAART, of whom 622 (31.5%) were antiretroviral 
naïve. Of these, 454 (73.0%) had information available at 6 months and were included in the 
study. One patient died before the sixth month of therapy and was therefore categorized as 
virological failure. Nearly one-half of the patients initiated HAART with a PI (208; 45.7%). The 
PI used was predominantly indinavir (92; 20.2%), followed by nelfinavir (81; 17.8%), saquinavir 
(27; 5.9%), and ritonavir (8; 1.7%). Around forty percent of the study subjects initiated HAART 
with a regimen that included a NNRTI. Among these, the vast majority received efavirenz (168; 
36.9%), followed by nevirapine (11; 2.4%). Fifty-eight patients received a ritonavir boosted 
regimen (12.7%), 3 patients received a triple NRTI regimen, and 1 patient initiated a different 
regimen.   
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The following characteristics were similar for patients who were included in the study and 
for the 168 therapy naïve patients who were not eligible because a viral load measurement was 
not available 6 months after treatment initiation: age, gender, prior AIDS diagnosis, and baseline 
CD4 cell count and HIV PVL. However, those not included were 1.83 times (95% CI: 
1.21−2.77) more likely to be non-adherent to treatment and 2.1 times (95% CI: 1.14−4.15) more 
likely to have received regimens with one PI, as compared to ritonavir-boosted regimens. They 
were also more likely to have started therapy before 1999, compared with those who started in 
1999 and after (OR: 1.93; 95% CI: 1.35 −2.78). Sixty-five percent of included patients were 
men; the median age was 36 years, with 22.5% being less than 30 years old, 44.2% 31 to 40 
years old, and 33.3% 41 years of age and older. The most common risk factors for HIV infection 
were heterosexual activity (43.9%) and being a man who reported having sex with men (35.7%). 
Baseline characteristics of the 454 patients are summarized in Table 3 to 5. 
 
Table 3. Demographic and clinical baseline characteristics of 454 patients starting antiretroviral 
therapy from 1996 to 2004 
Variable median (IQR), n/n (%) 
Median age (years) 36 (31−43) 
Male  296/454 (65.2%) 
White race 412/450 (91.6%) 
Risk factor  
MSM 144/403 (35.7%) 
IDU 77/403(19.1%) 
Transfusion 5/403 (1.2%) 
Heterosexual 177/403 (43.9%) 
Less than 5 years of formal education 109/388 (28.1%) 
CD4 count at baseline   
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Table 3 continued: 
 
Variable median (IQR), n/n (%) 
Median (cells/μL) 156 (47−253) 
Count <100 cells/μL 159/420 (37.9%) 
AIDS diagnosis 322/453 (71.1%) 
HIV RNA level at baseline (log10 copies/mL) 5.0 (4.58−5.60) 
Year therapy initiated  
1996 − 1997 76/454 (16.7%) 
1998 69/454 (15.2%) 
1999 84/454 (18.5%) 
2000 58/454 (12.8%) 
2001 63/454 (13.9%) 
2002 55/454 (12.1%) 
2003 − 2004 49/454 (10.8%) 
Regimen type  
2 NRTI + 1 PI 208/454 (45.7%) 
2 NRTI + 1 NNRTI 179/454 (39.5%) 
RNV boosted 58/454 (12.8%) 
NNRTI + PI  5/454 (1.1%) 
3 NRTI 3/454 (.6%) 
Other 1/454 (.2%) 
MSM, men who have sex with men; IDU, injecting drug use; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, non-
nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; IQR, inter-quartile range. 
 
Table 4. Demographics and baseline clinical characteristics according to initial treatment 
received.  
 1 Protease 
inhibitor (n=207) 
Non-nucleoside 
inhibitor (n=179) 
Ritonavir 
boosted (n=58) 
P 
Sex male [n (%)] 145/207 (70.1%) 106/179 (59.2%) 39/58 (67.2%) .21 
Age (years) [median (IQR)] 34 (31−40)* 37 (31−44) 39 (33−49)* .013 
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Table 4 continued: 
 
 1 Protease 
inhibitor (n=207) 
Non-nucleoside 
inhibitor (n=179) 
Ritonavir 
boosted (n=58) 
P 
Non white ethnicity [n(%)] 16/207 (7.7%) 20/179 (11.2%) 5/58 (8.6%) .51 
Risk behavior [n(%)]     
MSM 79/187 (42.2%) 44/157 (28.0%) 19/50 (38.0%)  
IDU 36/187 (19.2%) 28/157 (17.8%) 12/50 (24.0%)  
Transfusion 4/187 (2.1%) 0 1/50 (2.0%)  
Heterosexual 68/187 (36.4%) 85/157 (54.1%) 18/50 (36.0%)  
Less than 5 years of 
education [n(%)] 
43/176 (24.4%) 43/154 (28.1%) 19/51 (37.2%) .083 
AIDS diagnosis [n(%)] 146 (70.9%) 113 (63.1%) 53 (91.4%) .092 
Viral load at baseline (log10 
copies/mL) [median (IQR)] 
5.11 (4.72−5.65)* 4.80 (4.35−5.29)* 5.60 
(5.22−6.04)* 
<.0001 
CD4 count at baseline 
(cells/mL) [median (IQR)] 
132 (39−289) 203 (102−254)* 85 (37−159)* .0029 
*Pairwise comparisons with statistically significant difference 
 
Table 5. Demographic and clinical baseline characteristics of patients stratified by year 
Year 1996-97 
(n=76) 
1998  
(n=69) 
1999  
(n=84) 
2000  
(n=58) 
2001  
(n=63) 
2002  
(n=55) 
2003-04 
(n=49)  
Male 53 (69.7%) 52 (75.4%)* 55 (65.5%) 39 (67.2%) 39 (61.9%) 31 (56.4%) 27 (55.1%) 
Age 33 (30−37)* 36 (32−44) 34 (31−42) 39 (32−46)* 38 (34−45)* 37 (29−42) 36 (32−46) 
Non-white 3 (3.9%) 5 (7.3%) 13 (15.5%) 5 (8.6%) 5 (7.9%) 5 (9.1%) 6 (12.2%) 
Risk behavior        
MSM 31/72 (43.1%) 
30/56 
(53.6%) 
21/80 
(26.2%) 
22/48 
(45.8%) 
19/51 
(37.2%) 
11/49 
(22.4%) 
10/47 
(21.3%) 
IDU 9/72 (12.5%) 
9/56 
(16.0%) 
19/80 
(23.7%) 
6/48 
(12.5%) 
7/51 
(13.7%) 
16/49 
(32.6%) 
11/47 
(23.4%) 
Transfusion 0 2/56 (3.6%) 2/80 (2.5%) 0 0 1/49 (2.0%) 0 
Heterosexual 32/72 (44.4%) 
15/56 
(26.8%) 
38/80 
(47.5%) 
20/48 
(41.7%) 
25/51 
(49.0%) 
21/49 
(42.8%) 
26/47 
(55.3%) 
Education 
Low vs High 8 (11.4%)* 14 (24.6%) 19 (27.9%) 19 (36.5%) 20 (36.4%) 16 (36.4%) 13 (30.9%) 
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Table 5 continued: 
 
Year 1996-97 
(n=76) 
1998  
(n=69) 
1999  
(n=84) 
2000  
(n=58) 
2001  
(n=63) 
2002  
(n=55) 
2003-04 
(n=49)  
AIDS 49 (64.5%) 53 (76.8%) 57 (68.7%) 38 (65.5%) 52 (82.5%)* 43 (78.2%) 30 (61.2%) 
Viral load at 
baseline 
5.11 
(4.74−5.67) 
5.18 
(4.79−5.61) 
5.00 
(4.50−5.62) 
5.04 
(4.57−5.63) 
5.22 
(4.64−5.74) 
5.01 
(4.37−5.47) 
4.81 
(4.36−5.23) 
CD4 count at 
baseline 
140 
(34−330) 
132 
(40−222) 
145 
(48−289) 
203 
(41−254) 
117 
(40−214) 
182 
(71−244) 
194 
(122−230) 
 
2.4.1 Outcomes at 6 months 
After 3-9 months on HAART, 127 (27.9%) patients had detectable HIV plasma viral load. The 
median increase in CD4 count was 117 cells/uL and the median HIV PVL decrease was 2.99 
log10 copies/mL. Table 6 summarizes the main outcomes at 6 months of therapy. 
 
Table 6. Main outcomes at 6 months on HAART for 454 patients 
Outcome median (IQR), n/n (%) 
Median PVL level at 6 months (log10 copies/mL) 1.90 (1.70−2.60) 
Median decrease in HIV RNA(log10 copies/mL) 2.99 (2.40−3.53) 
Median CD4 count at 6 months (x 106 cells/L) 273 (174−415) 
Median change in CD4 count (x 106 cells/L) 117 (60−197) 
CD4 increase ≥50 x 106 cells/L 316/373 (84.7%) 
CD4 increase ≥100 x 106 cells/L 236/373 (63.3%) 
Virologic treatment failure 127/454 (27.9%) 
 
In comparison with patients with virological success, those with virological failure were 
younger (median 34 vs. 37 years of age; p<0.01); had higher baseline HIV plasma viral load 
(5.34 vs. 5.00 log10 copies/uL; p<0.01) and lower baseline CD4 counts (86 vs. 182 cells/uL; 
p<0.01). Non-adherent patients were 1.39 times less likely to respond than adherent patients, as 
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well as patients who received regimens containing a single PI, as compared to those prescribed 
ritonavir-boosted regimens (OR: 8.58; 95% CI: 3.53−20.85) and NNRTI based regimens (OR: 
0.73; 95% CI: 0.27−2.01). In the multivariate analysis, higher baseline HIV PVL was the only 
factor associated with virological failure (OR: 2.1; 95% CI: 1.1−4.0). The results are summarized 
in Table 7. 
 
Table 7. Factors associated with virological failure among all 454 patients.  
Univariate analysis 
Categorical variables 
RR 95% CI P 
Sex (Male) 1.10 0.98−1.23 0.12 
Race Nonwhite vs White 0.91 0.76−1.07 0.32 
Education     
Low vs high  0.94 0.82−1.08 0.43 
Age group    
<30  2.51 1.39−4.52 0.05 
30−40 2.36 1.41−3.96 0.06 
>40 (ref) 1.00 − − 
Year     
1996 − 1997 125.6 16.29−969.42 <0.01 
1998 66.19 8.63−507.51 <0.01 
1999 8.78 1.11−69.38 0.75 
2000 9.99 1.23−81.15 0.95 
2001 2.39 0.24−23.80 <0.01 
2002 4.79 0.54−42.58 0.11 
2003 − 2004 (ref) 1.00 − − 
Lack of adherence 1.39 1.16−1.68 <0.01 
AIDS 1.18 1.05−1.31 <0.01 
Regimen    
2 NRTI + 1 PI  8.58 3.53−20.85 <0.01 
2 NRTI + 1 NNRTI  0.73 0.27−2.01 <0.01 
Reg. RNV boosted(ref) 1.00 − − 
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Table 7 continued: 
 
Continuous variables Virological 
failure 
median 
(IQR) 
Viral suppression 
median (IQR) 
 
Viral load at baseline 5.34 
(4.90−5.83) 
5.00 (4.50−5.52) <0.01 
CD4 count at baseline 86 (35−226) 182 (64−256) <0.01 
 
Type of HAART regimen was highly associated with the year in which therapy was started, 
with NNRTI-containing and ritonavir-boosted regimens becoming much more common over 
time. In addition, virologic failure was significantly higher for patients who started therapy 
before 1999. Among the 145 patients who started HAART between 1996 and 1998, the year 
before NNRTIs became available in Brazil, the virological failure rate was 65.5% versus 10.4% 
for the 309 patients who started therapy in 1999 or later (p<0.01).  
Given these time-dependent trends and to provide information relevant to current treatment 
practices in Brazil, subsequent analyses were restricted to patients who began therapy in 1999 or 
later. 
 
2.4.2 Sub-analysis of patients who started HAART in 1999 and later 
 
In the univariate analysis of patients starting therapy after 1999, age < 30 years, previous AIDS-
diagnosis, higher baseline plasma viral load, fewer than 5 years of formal education, non-
adherence to therapy, and type of regimen used were associated with virologic failure. In the 
multivariate analysis, higher baseline plasma viral load (OR: 2.32; 95% CI: 1.03−5.25); and non-
 30
adherence (OR: 4.77; 95% CI: 1.47−15.50) were independently associated with virological 
failure (Table 8).  
Table 8. Factors associated with virological failure in the 309 patients who started HAART in 
1999 and after. 
Univariate analysis Multivariate analysis 
Categorical variables 
RR 95% CI P OR 95% CI P 
Sex (Male) 1.03 0.95−1.11 0.39 − − − 
Race Nonwhite vs White 1.01 0.89−1.15 0.77 − − − 
<5years of education  1.08 0.98−1.19 0.06    
Lack of adherence 1.31  1.11−1.53 <0.01 4.77 1.47−15.50 <0.01 
Age group       
<30  3.39 1.17−9.81 0.09    
30−40 2.74 1.03−7.26 0.29    
>40 (ref) 1.00 − −    
AIDS 1.10 1.04−1.18 0.02    
Regimen       
2 NRTI + 1 PI  2.83* 0.86−9.35 0.02    
2 NRTI + 1 NNRTI 1.11 0.35−3.52 0.31    
RNV boosted(ref) 1.00 − −    
Continuous variables Virological 
failure 
median (IQR) 
Viral 
suppression 
median (IQR) 
    
Viral load at baseline 
(log10 copies/mL) 
5.60 
(5.05−6.10) 
4.98 (4.50−5.50) <0.01 2.32 1.03−5.25 0.04 
CD4 count at baseline 
(cells/μL) 
104 (41−208) 175 (64−254)     
*OR 
 
2.4.3 Sub-analysis of patients who started therapy in 1999 and after and had advanced 
disease 
In the subset of 158 patients who started therapy after 1999 and whose baseline CD4 count was 
<200 cells/uL, factors independently associated with virological failure were non-adherence 
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(OR: 8.78; 95% CI: 1.49−51.80), and number of years of formal education (OR: 6.05 for those 
with < 5 years of formal education; 95%CI: 1.02−35.99). Results are summarized in Table 9. 
Table 9. Factors associated with virological failure in 158 patients who started HAART in 1999 
and after, and had CD4 count<200 cels/ uL. 
Univariate analysis Multivariate analysis Factor (categorical 
variables) RR 95% CI P OR 95% CI P 
Sex (Male) 0.98 0.88−1.10 0.81 − − − 
Race Nonwhite vs White 1.01 0.84−1.21 0.90 − − − 
Education        
Low vs high  1.17 1.01−1.36 0.02 6.05 1.02−35.99 0.05 
Age group       
<30        
30−40       
>40 (ref)       
Lack of adherence 1.40 1.12−1.74 <0.01 8.78 1.49−51.80 0.02 
Regimen       
2 NRTI + 1 PI  4.92 0.95−25.57 0.02    
2 NRTI + 1 NNRTI 1.73 0.34−8.71 .66    
Reg. RNV boosted (ref) 1.00 − −    
Factor (continuous 
variables) 
Virological 
failure 
median (IQR) 
Viral 
suppression 
median (IQR) 
    
Viral load at baseline 5.73 (5.53−6.50) 5.11 (4.54−5.67) 0.01    
CD4 count at baseline 52 (32−103) 82 (27−134) 0.41    
 
2.5 DISCUSSION 
There are limited data on the response to therapy in developing country settings [44]. In a meta-
analysis of 10 observational studies conducted in developing countries, Ivers et al showed that 
ART resulted in an virological suppression in nearly 70% of individuals at time points up to 
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month 18 [57]. Since 1996, there has been free and universal access to antiretroviral therapy in 
Brazil to all individuals who qualify for treatment according to national guidelines. At present, 
over 150,000 Brazilians participate in this program. As a direct consequence, HIV-related 
morbidity and mortality have sharply declined [64]. Therapy guidelines are periodically revised 
by an independent advisory committee and, at present, Brazilian guidelines are similar to the 
IAS-USA guidelines [71]. Nonetheless, despite the enormous public health impact of the 
Brazilian program, there are few published reports on response to therapy [65-67].  
In the present study, we investigated predictors of virological failure in therapy-naïve HIV-1 
infected patients followed at a public hospital in southern Brazil after 3-9 months on HAART. 
We found that nearly three quarters of patients had undetectable viral load 3-9 months after 
starting therapy. When analyses were restricted to those starting treatment in 1999 and after, 
success rates were approximately 90% or more for all CD4 strata. Given that patients seen in the 
earlier years did not differ with regards to age, gender, risk behavior, prior AIDS diagnosis, and 
baseline HIV plasma viral load and CD4 cell count, the observed improvement in response rates 
over time is most likely due to the availability of more potent and easier to take regimens, such 
as those containing NNRTI and ritonavir-boosted regimens, and is in line with results from 
randomized controlled trials, and other observational studies that have demonstrated the 
superiority of these regimens over those containing a single PI [72, 73].  
Similar to various other reports, adherence to therapy was associated with superior 
virological outcome [74-76]. Although it is possible that self-reported adherence may 
overestimate real adherence [77], several studies have demonstrated a correlation between self-
reported adherence and electronic medication event monitoring systems [78-80]. Number of 
years of formal education was also found to be independently associated with virologic success 
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among patients with more advanced immunodeficiency. This finding is consistent with results 
from other studies conducted in Brazil and elsewhere. For example, Kalichman et al reported that 
the number of years of education and health literacy were predictors of treatment adherence in 
318 patients taking antiretroviral therapy in a community sample [81]. In another study 
conducted in several public outpatient clinics in Rio de Janeiro, we demonstrated that lack of 
understanding about antiretroviral therapy was an important determinant of therapeutic failure 
[82].  
This was a retrospective observational study that is subject to several limitations. First, 
patients for whom a viral load measurement was not available 3 to 9 months after treatment 
initiation were not included in the study. Since non-compliance with clinic appointments, a 
predictor of therapeutic success [11], is one of the likely reasons for the non-performance of 
monitoring laboratory tests, excluded patients are more likely to be non-adherent to treatment. 
Thus, it is possible that we have underestimated the overall risk of virological failure. Excluded 
patients were also more likely to have received single PI based regimens and have started 
therapy before 1999, which reflects clinical practices at that time. In fact, when these patients 
were considered as treatment failures, we found that lack of adherence (OR: 2.87; 95% CI: 
1.88−4.37) and year of initiation before 1999 (OR: 6.58; 95% CI: 3.91−11.08) remained 
associated with virological failure, after adjusting for age, AIDS diagnosis, baseline CD4 count 
and viral load, and regimen. Given the observational nature of the study, the lack of 
randomization to different treatment regimens makes comparisons between the outcomes of 
different strategies susceptible to considerable selection-by-indication bias. We attempted to 
minimize the potential bias associated with changes in clinical practices over time by limiting 
some analyses to patients who started therapy in 1999 and after and to patients with more 
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advanced immune deficiency. Our results may also have been influenced by potentially 
confounding risk factors that were not included in the analysis [32, 72, 83]. The differences over 
time may reflect improvement in health care quality and provider’s experience [84, 85]. We also 
may have been unable to accurately characterize virological success for some patients. For 
example, those patients for whom laboratory information was only available earlier may have 
been considered as treatment failures, as well as those who were slower responders. This study 
was of relatively short duration, which does not allow us to comment on the long-term success of 
HAART in our population. Further follow-up of the study patients is being carried out and will 
help provide insights on the role of virological response at 6 months on long-term outcomes, 
such as sustained response to therapy, the incidence of opportunistic infections, and death in this 
population. Finally, Brazil may be representative of middle-income developing countries but 
most likely is not representative of more resource-poor developing nations. 
In summary, virologic response rates observed in a public clinic in Brazil compared 
favorably to what has been reported from developed countries settings as well as from 
developing countries. Our findings add to a growing body of literature that supports the effort of 
the World Health Organization to expand access to HAART in developing countries, where the 
vast majority of HIV infections occur. In this cohort, virologic success was associated with year 
of therapy initiation, consistent with the introduction of NNRTIs and ritonavir-boosted regimens 
into clinical practice. With currently available therapies, adherence and level of education were 
shown to be predictors of virological response, particularly in patients with more advanced 
immune deficiency. It was also shown that less than 5 years of formal education was associated 
with non-adherence, particularly among patients receiving regimens containing a single PI or 
ritonavir-boosted regimens (data not shown). These results suggest a need for interventions that 
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focus on improving adherence to HAART in persons with little formal education, particularly for 
those prescribed more complex regimens.  
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3.1 ABSTRACT 
Objectives: To assess frequency of and risk factors for discordant responses at 6 months on 
HAART in previously treatment-naïve HIV-patients from resource-limited countries.  
Methods: The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration is 
a network of clinics providing care and treatment to HIV infected patients in Africa, Latin 
America, and Asia. Patients who initiated therapy between 1996 and 2004, were aged 16 years or 
older, and had a baseline CD4 cell count were included in this analysis. Responses were defined 
based on plasma viral load and CD4 cell count at 6 month as complete (VR+IR+); virologic only 
(VR+IR-); immunologic only (VR-IR+) and non-response (VR-IR-). Multinomial logistic 
regression was used to assess the association between therapy responses and clinical and 
demographic variables. 
Results: Of the 3,111 patients eligible for analysis, 1,914 had available information at 6 months 
of therapy: 1,074(56.1%) were VR+IR+, 364(19.0%) were VR+IR-, 283(14.8%) were (VR-IR+), 
193(10.1%) were VR-IR-. Compared to complete responders, virologic only responders were 
older, had higher baseline CD4 counts, lower baseline viral load, and were more likely to have 
received a nonstandard HAART regimen; immunologic only responders were younger, had a 
lower baseline CD4 count, a higher baseline viral load and were more likely to have received a 
PI based regimen. 
Conclusions: The frequency of and risk factors for discordant response were comparable to 
those observed in developed countries. A longer follow-up is needed to assess the long-term 
impact of discordant responses on mortality in these resource-limited settings.  
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3.2 INTRODUCTION 
In high income countries, the availability of highly active antiretroviral therapy (HAART) has 
led to major reductions in morbidity and mortality from HIV infection [1-3]. Several studies in 
this setting have demonstrated a stronger correlation between long-term prognosis and virologic 
and immunologic responses after 6 months on HAART than with baseline values [18, 86, 87]. In 
general, the initiation of HAART leads to a significant reduction in plasma HIV plasma viral 
load (PVL) and an increase in CD4 cell counts [7, 12]. However, some patients on HAART 
exhibit a pattern of sustained CD4 response despite persistent viremia, or do not exhibit a 
significant rise in CD4 cell counts despite viral suppression. Both situations are referred to as 
discordant responses and have been consistently associated with an intermediate risk of 
developing an AIDS event or death in developed countries [15, 20, 26, 88].  
In high-income countries, discordant responses have been reported to occur in 20% to 30% 
of patients 6 months to 2 years after starting HAART [15, 19, 24, 86, 89, 90]. In developing 
countries, the effectiveness of HAART in suppressing viral replication and inducing CD4 cell 
rise is comparable to what has been reported from developed countries [56, 57, 82, 91-93]. 
Nonetheless, to date there is scant information on the frequency and prognostic significance of 
discordant responses to HAART in low-income countries, where patients often start therapy at 
advanced stages of immune deficiency and frequently have co-morbidities that may impair 
response to therapy [94].  
We report on the frequency of and risk factors for discordant responses at 6 months on 
HAART in previously treatment naïve HIV-patients in resource-limited countries.  
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3.3 METHODS 
3.3.1 Patients and measurements 
The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration is a network 
of HIV treatment programmes in Africa, Latin America, and Asia. The ART-LINC collaboration 
has been described previously [58, 62]. The selection of patients and data extraction were done at 
the participating sites. Data were anonymized locally, then pooled and analysed centrally. At all 
sites local ethics committees or institutional review boards approved the collection of data. 
Only sites that collected HIV PVL routinely were included in the analysis. All previously 
treatment-naïve individuals who initiated therapy between March 1996 and April 2004, had a 
known date of therapy initiation, were aged 16 years or older, and had a documented CD4 cell 
count at baseline were included in this analysis.  
Type of HAART regimen was defined as protease inhibitor (PI)-based (one PI plus two 
nucleoside reverse-transcriptase inhibitors [NRTI], including ritonavir-boosted regimens), non-
nucleoside reverse transcriptase (NNRTI)-based (one NNRTI plus two NRTIs), or a nonstandard 
HAART regimen (including triple NRTI regimens and any other regimen containing a minimum 
of 3 drugs). Stage of disease was classified as less (CDC stage A/B, WHO stages I or II) or more 
advanced (CDC stage C, WHO stages III or IV). Baseline CD4 cell count and HIV plasma viral 
load (PVL) were measured at therapy initiation (-180 or + 7 days).  
3.3.2 Study Outcomes and Statistical Analysis 
Virologic response (VR) was defined as achieving a plasma HIV PVL < 500 copies/mL, whereas 
immunologic response (IR) was defined as an increase of at least 50 CD4 cells/μL at 6 months. 
Measurements closest to 6 months after starting HAART, within 3 to 9 months, were used in 
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these analyses. Outcomes were defined as complete response (VR+IR+); virologic only response 
(VR+IR-); immunologic only response (VR-IR+) and non-response (VR-IR-). An intent-to-
continue-treatment approach, which ignored subsequent therapy changes or interruptions, was 
used. Between-group comparisons were made by using Chi-Square test for categorical variables 
and Kruskall-Wallis test for continuous variables. A multinomial logistic regression model was 
fit to assess the relationship between baseline characteristics and the 6 month outcomes. 
Heterogeneity introduced by different sites was accounted for by including site as a fixed effect 
in the model, and Huber-White robust standard errors were calculated to account for intra-site 
correlation.  
Missing baseline information on stage of disease and PVL were multiply imputed, based on 
whether the patient died, site, CD4 cell count, sex, age and type of HAART regime. In these 
imputations, values of the missing data were randomly sampled from their predicted 
distributions. Analyses were run on each of 20 datasets that included the imputed values, and the 
results combined with Rubin’s rules [95]. Analyses were performed using Stata version 9.0 
(Stata Corp., College Station, TX). 
3.4 RESULTS 
During the study period, 4,810 patients initiated HAART. Of these, 158 (3.2%) died within 6 
months of therapy, and 1,541 (32.0%) were from sites where viral load was not routinely 
performed and therefore were not included in the analysis. The demographic and clinical 
characteristics of the remaining 3,111 patients are shown in Table 10 according to immunologic 
and virologic responses at 6 months on therapy.  
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Table 10. Patients’ baseline characteristics according to immunologic and virologic response at 
6 months of therapy and comparison between those with known and unknown response.  
Variable Total 
N = 3111 
VR+IR+ 
N = 1074 
VR+IR- 
N = 364 
VR-IR+ 
N = 283 
VR-IR- 
N = 193 
Unknown 
Response 
N = 1197 
Known vs 
Unknown 
P 
Male gender n (%) 1,585 (50.9) 532 (49.5) 195 (53.6) 144 (50.9) 97 (50.3) 617 (51.6) 0.43 
Age years*  35 (30 − 41) 35 (30 − 41) 36 (31 − 42) 35 (28 − 41) 37 (31 − 42) 35 (30 − 42)  
Age groups n (%)       0.36 
16 − 29 700 (22.5) 256 (23.8) 69 (18.9) 85 (30.0) 36 (18.6) 254 (21.2)  
30 − 39 1,435 (46.1) 507 (47.2) 172 (47.2) 119 (42.0) 86 (44.6) 551 (46.0)  
40 − 49 705 (22.9) 232 (21.6) 83 (22.8) 53 (18.7) 57 (29.5) 290 (24.2)  
≥ 50 261 (8.4) 79 (7.4) 40 (10.9) 26 (9.2) 14 (7.2) 102 (8.5)  
Baseline CD4 count 
cells/μL* 
137 (49 − 240) 135 (49 − 240) 186 (87 − 282) 103 (36 − 207) 141 (50 − 263) 127 (45 − 225)  
Baseline CD4 count 
cells/μL at baseline n 
(%) 
      0.29 
<50 782 (25.1) 272 (25.3) 51 (14.0) 91 (32.2) 47 (24.3) 321 (26.8)  
50 − 99 466 (14.9) 153 (14.2) 48 (13.2) 49 (17.3) 26 (13.5) 190 (15.8)  
100 − 199 790 (25.4) 270 (25.1) 97 (26.6) 68 (24.0) 44 (22.8) 311 (25.9)  
200 − 349 764 (24.6) 276 (25.7) 118 (32.4) 55 (19.4) 44 (22.8) 271 (22.6)  
≥ 350 309 (9.9) 103 (9.6) 50 (13.7) 20 (7.1) 32 (16.6) 104 (8.7)  
Baseline HIV RNA 
log10 copies/mL* 
5.1 (4.6−5.6)  5.0 (4.6 − 5.6) 4.8 (4.4 − 5.4) 5.4 (4.8 − 5.8) 5.3 (4.8 − 5.7) 5.1 (4.6 − 5.6)  
Baseline HIV RNA 
copies/mL* - n (%) 
      <0.01 
< 10,000 194 (6.2) 78 (7.3) 43 (11.8) 15 (5.3) 12 (6.2) 46 (3.8)  
10000 − 99999 747 (24.0) 350 (32.6) 126 (34.6) 51 (18.0) 46 (23.8) 174 (14.5)  
≥ 100000 1,181 (37.9) 484 (45.1) 138 (37.9) 146 (51.6) 107 (55.4) 306 (25.5)  
Unknown 989 (31.8) 162 (15.6) 57 (15.6) 71 (25.1) 28 (14.5) 671 (56.1)  
Clinical stage       <0.01 
Less advanced 778 (25.0) 243 (22.6) 111 (30.5) 66 (23.3) 53 (27.5) 305 (25.5)  
More 
advanced 
1,591 (51.1) 594 (55.3) 179 (49.2) 158 (55.8) 103 (53.4) 557 (46.5)  
Unknown 742 (23.8) 237 (22.1) 74 (20.3) 59 (20.8) 37 (19.2) 335 (27.9)  
Regimen type       <0.01 
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Table 10 continued: 
 
Variable Total 
N = 3111 
VR+IR+ 
N = 1074 
VR+IR- 
N = 364 
VR-IR+ 
N = 283 
VR-IR- 
N = 193 
Unknown 
Response 
N = 1197 
Known vs 
Unknown 
P 
NNRTI based 1,783 (57.3) 658 (61.3) 202 (55.5) 96 (33.9) 68 (35.2) 759 (63.4)  
PI based 889 (28.6) 289 (26.9) 94 (25.8) 125 (44.2) 54 (27.9) 327 (27.3)  
Other  439 (14.1) 127 (11.8) 68 (18.7) 62 (21.9) 71 (36.8) 111 (9.3)  
Calendar year       <.01 
1996-1997 178 (5.7) 58 (5.4) 17 (4.7) 25 (8.8) 16 (8.3) 62 (5.2)  
1998 285 (9.2) 73 (6.8) 35 (9.6) 55 (19.4) 39 (20.2) 83 (6.9)  
1999 430 (13.8) 148 (13.8) 67 (18.4) 68 (24.0) 52 (26.9) 95 (7.9)  
2000 487 (15.6) 194 (18.1) 62 (17.0) 53 (18.7) 28 (14.5) 150 (12.5)  
2001 556 (17.9) 211 (19.6) 67 (18.4) 38 (13.4) 23 (11.9) 217 (18.1)  
2002 674 (21.7) 253 (23.6) 79 (21.7) 31 (10.9) 26 (13.5) 285 (23.8)  
2003-2004 501 (16.1) 137 (12.8) 37 (10.2) 13 (4.6) 9 (4.6) 305 (25.5)  
* Median (IQR) 
 
About half were male (50.9%), with a median age at HAART initiation of 35 years. The 
median baseline CD4 cell count and HIV-RNA plasma viral load were 137 (IQR 49 – 240) 
cells/μL and 5.1 (IQR 4.6 – 5.6) log10 copies/mL respectively, 1,591(51.1%) had more advanced 
disease, and 1,783 (57.3%) were prescribed a NNRTI based regimen. Excluded patients were 
more likely to be female (55% vs 45%, p<0.01) and to have a lower baseline CD4 cell count (70 
vs 136, p<0.01). 
The majority of patients (57.3%) started therapy with a NNRTI based regimen, and 29 % 
started with a PI based regimen. The most prescribed NNRTI and PI were efavirenz (66.1%) and 
indinavir (48.8%), respectivelly. PI based regimens were more commonly prescribed before the 
year of 2000 (64.0%). From 2000 onwards, NNRTI based regimens predominated (76.0%). 
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Recipients of nonstandard HAART regimens had the highest median baseline CD4 count – 
185 (IQR 63 – 315) cells/μL, whereas recipients of PI based and NNRTI based regimens had 
similar median baseline counts: 131 (IQR 45 – 253) and 131 (IQR 48 – 222) cells/μL, 
respectively. The baseline viral load for recipients of NNRTI, PI based and non-standard 
regimens were 5.1 (IQR 4.6 – 5.6), 5.2 (IQR 4.7 – 5.7), and 4.9 (IQR 4.5 – 5.5) log10 copies/mL, 
respectively (data not shown). 
3.4.1 Immunologic and virologic responses at 6 months of therapy 
At 6 months on therapy, 1,914 (61.5%) patients had information on PVL and CD4 cell count. For 
1,197 (38.5%), the outcome could not be ascertained because of missing data on either PVL or 
CD4 count. Among these patients, 292 (24.4%) were lost to follow up at 6 months.  
Among the patients with available information, 1,074 (56.1%) were complete responders, 
364 (19.0%) were virologic only responders, 283 (14.8%) were immunologic only responders, 
and 193 (10.1%) were nonresponders (Table 11). The overall virologic response rate was 75.1%, 
the median increase in CD4 count was +106 (IQR +40 – +178) cells/μL, and the median viral 
load reduction was 2.8 (IQR -3.4 – -1.9) log10copies/mL. Complete responders showed the 
greatest CD4 cell count increase and PVL decrease, and non-responders showed the smallest 
changes in these measurements.  
 
Table 11. Outcomes at 6 months of therapy for 1914 patients with known outcome 
Outcome (n) Total 
 
VR+IR+ VR+IR- VR-IR+ VR-IR- 
Virologic and immunologic 
response  
n (%) 
 1 074 (56.1) 364 (19.07) 283 (14.8) 193 (10.1) 
CD4 count change  
(median (IQR) cells/mm3) 
+106 (40 – 178) +148 (+102 − 
+225) 
+12 (-14 − +33) +125 (+85 - 
+194) 
-1 (-42 − +16) 
Viral load change  
(log10 (IQR) copies/mL) 
-2.8 (-3.4 – -1.9) -3.1 (-3.6 − -2.5) -2.9 (-3.4 − -2.2) -1.6 (-2.2 − -0.8) +0.7 (-1.7 − 0) 
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Table 12 shows the results of the multinomial logistic regression model for 1,914 patients 
with known response, with complete responders as the reference group, controlling for 
demographic and clinical variables, calendar year, and participating site. There were no 
significant differences by gender between complete responders and all other categories of 
response.  
 
Table 12. Odds Ratios (OR) and 95% confidence intervals (CIs) of discordant responses relative 
to complete response in 1,914 patients with known outcome.* 
Variable VR+IR-
OR (95%CI) 
P VR-IR+
OR (95%CI) 
P VR-IR-
OR (95%CI) 
P VR+IR- vs 
VR-IR+
P 
Gender       0.13 
Male 1.0  1.0  1.0   
Female 0.85 (0.70 – 1.03) 0.10 1.03 (0.73 – 1.45) 0.86 0.91 (0.61 – 1.36) 0.65  
Age groups       <0.01 
16 − 29 1.0  1.0  1.0   
30 − 39 1.29 (0.94 – 1.78) 0.11 0.56 (0.42 – 0.75) <0.01 0.88 (0.57 – 1.37) 0.59  
40 − 49 1.37 (0.87 – 2.16) 0.17 0.47 (0.29 – 0.77) <0.01 1.31 (0.92 – 1.87) 0.13  
≥ 50 2.12 (1.45 – 3.09) <0.01 0.64 (0.43 –0.95) 0.03 1.16 (0.78 – 1.73) 0.46  
Baseline CD4 count (cells/μL)        <0.01 
<50 1.0  1.0  1.0   
50 − 99 1.70 (0.95 – 3.04) 0.07 0.96 (0.64 – 1.43) 0.85 1.09 (0.59 – 2.02) 0.77  
100 − 199 1.85 (1.43 – 2.40) <0.01 0.73 (0.54 – 0.98) 0.04 1.04 (0.66 – 1.63) 0.86  
200 − 349 2.27 (1.71 – 3.03) <0.01 0.58 (0.30 – 1.13) 0.11 1.18 (0.66 – 2.11) 0.57  
≥ 350 2.18 (1.47 – 3.23) <0.01 0.34 (0.18 – 0.63) <0.01 1.43 (0.60 – 3.39) 0.41  
Baseline HIV RNA copies/mL**       <0.01 
< 10,000 1.0  1.0  1.0   
10,000 − 99,999 0.74 (0.45 – 1.22) 0.24 0.97 (0.53 – 1.77) 0.93 1.16 (0.45 – 2.94) 0.75  
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Table 12 continued: 
 
Variable VR+IR-
OR (95%CI) 
P VR-IR+
OR (95%CI) 
P VR-IR-
OR (95%CI) 
P VR+IR- vs 
VR-IR+
P 
≥ 100,000 0.63 (0.42 – 0.95) 0.03 1.77 (1.04 – 3.00) 0.03 1.81 (0.79 – 4.14) 0.16  
Clinical stage***       0.52 
Less advanced 1.0  1.0  1.0   
More advanced 1.09 (0.77 – 1.54) 0.60 1.09 (0.73 – 1.64) 0.64 1.48 (0.87 – 2.51) 0.14  
Regimen type       <0.01 
NNRTI based 1.0  1.0  1.0   
PI based 0.86 (0.74 – 1.01) 0.07 1.58 (1.08 – 2.30) 0.02 0.95 (0.48 – 1.85) 0.87  
Other  1.45 (1.00 – 2.11) 0.05 1.25 (0.86 – 1.81) 0.23 1.10 (0.56 – 2.18) 0.76  
Calendar year        <0.01 
1996-1997 1.0  1.0  1.0   
1998 1.31 (0.62 – 2.76) 0.47 1.28 (0.46 – 3.53) 0.63 1.19 (0.50 – 2.81) 0.68  
1999 1.25 (0.86 – 1.81) 0.23 0.70 (0.30 – 1.63) 0.41 0.72 (0.40 – 1.27) 0.26  
2000 0.99 (0.60 – 1.64) 0.98 0.36 (0.13 – 0.97) 0.04 0.26 (0.09 – 0.69) <0.01  
2001 0.99 (0.60 – 1.64) 0.97 0.29 (0.13 – 0.66) <0.01 0.31 (0.13 – 0.72) <0.01  
2002 1.09 (0.68 – 1.73) 0.72 0.31 (0.13 – 0.71) <0.01 0.41 (0.14 – 1.19) 0.10  
2003-2004 0.88 (0.48 – 1.60) 0.69 0.22 (0.13 – 0.35) <0.01 0.26 (0.07 – 0.94) 0.04  
*Odds ratios adjusted for site and year of therapy initiation as fixed effects.  
**Baseline values imputed for 318 patients  
***Baseline values imputed for 407 patients 
 
In comparison with complete responders, virologic only responders were significantly more 
likely to be aged over 50, to have a baseline CD4 count >99 cells/μL and/or to have received 
nonstandard HAART regimens, and less likely to have baseline HIV RNA plasma viral load > 
100,000 copies/mL.  
Patients who showed an immunologic only response were less likely than complete 
responders to be older than 30 years, to have a baseline CD4 > 99 cells/ μL, and more likely to 
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have a baseline HIV RNA plasma viral load >100,000 copies/mL, or have received a PI-based 
regimen (Table 12). The probability of having an immunologic only or nonresponse rather than a 
complete response decreased after the year of 2000 (data not shown).  
Some covariates had opposite effects on the two categories of discordant responses.  
Increasing age, increasing baseline CD4 count, and other regimens were positively associated 
with virologic only responses and PI based regimens were positively associated with 
immunologic only responses, while ≥ 100,000 baseline HIV RNA copies/mL was negatively 
associated with virologic only responses and positively associated with immunologic only 
responses. Figure 1 shows the adjusted odds ratios of discordant responses by baseline CD4 cell 
count strata with complete responders as the reference group.  
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Figure 1. Adjusted odds ratios of responses (in log scale) after 6 months of HAART relative to 
complete response by baseline CD4 cell count.  
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We assessed the extent to which the rate of unknown response could have introduced bias in 
our analysis by comparing baseline characteristics, as well as virologic and immunologic 
responses between patients with known and unknown responses at 6 months. Patients with 
known and unknown responses at 6 months did not differ with respect to gender, age, or baseline 
CD4 cell count (Table 10). Patients with unknown response were more likely to have received a 
NNRTI based regimen, and to have an unknown baseline PVL and stage of disease. At 6 months 
of therapy, however, patients with unknown response and who had available information on 
either virologic or immunologic response (but not both) had overall similar median changes in 
CD4 cell count and PVL than did patients with both responses known (+112 vs +105, p = 0.26; 
and -2.7 vs -2.8, p = 0.88, respectively). A multinomial model including a missing outcome 
category led to similar results, supporting the hypothesis that this subgroup of patients did not 
significantly differ from the 1,914 patients with known outcome.  
3.5 DISCUSSION 
To our knowledge, this is the first report on the frequency of and risk factors for discordant 
responses in a large cohort of patients initiating HAART in low-income countries. The 
encountered frequency of discordant response (33.8%) at 6 months of therapy is similar to what 
has been reported from high-income countries[19, 20, 24, 88, 90]. We have found that, compared 
to complete responders, virologic only responders were older, had higher baseline CD4 counts, 
lower baseline viral load, and were more likely to have received a nonstandard HAART regimen; 
and immunologic only responders were younger, had a lower baseline CD4 count, and were 
more likely to have received a PI based or a nonstandard regimen.  
Our finding of older age being associated with virologic only response and inversely 
associated with immunologic only response is consistent with studies conducted in high-income 
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countries [20, 25, 26, 88], as well as the hypothesis that the magnitude of immune restoration is 
dependent on thymic activity, which decreases with age [27]. Other reports from high-income 
countries also have demonstrated that older age is independently associated with impaired 
immunologic responses despite sustained virologic responses [44]. It is also suggestive of a 
better adherence among older patients, in agreement with other studies [96, 97]. 
As in reports from high-income countries, a higher baseline CD4 count was associated with 
an increased probability of a virologic only response and with a reduced probability of an 
immunologic only response [20, 88, 98]. One possible explanation for this finding is the non-
linear nature of CD4 cell increase after HAART initiation across the different baseline CD4 
count strata. In agreement with the findings of Moore et al.[88], our results also suggest that 
increases in CD4 counts following initiation of therapy might be greater in individuals with 
lower CD4 counts at therapy initiation. A baseline viral load above 100,000 copies/mL was 
associated with a lower probability of having a virologic only response, a finding also reported in 
the studies of Moore et al. and Nicastri et al.[20].  
Our analysis showed that immunologic only responders were 1.6 times more likely than 
complete responders to have received PI-based regimens rather than NNRTI based regimens. 
This finding has to be interpreted with caution, however. As noted before, differences in 
response between HAART regimens in this observational study are likely to be subject to 
selection-by-indication bias. Nonetheless, it has been suggested that the additional effect of PIs 
on immunologic response could be due to their ability to reduce T-cell apoptosis [89]. A superior 
immunologic response to PIs over NNRTIs was suggested among virologic responders [99], but 
not among patients showing discordant responses [25, 88, 100]. This issue is unlikely to be fully 
elucidated by observational studies. 
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Qualitative differences in the effects of predictors of the two types of discordant responses 
support the hypothesis of different underlying mechanisms. Although the long term clinical 
outcomes seem to be comparable [88], identifying risk factors for both types of early discordant 
response may lead to specific preventive strategies for each type. 
Discordant responses have been associated with increased risk of clinical progression and 
mortality in developed countries. In one cohort of antiretroviral experienced patients with 
advanced HIV disease who started PI based HAART and were followed for over 30 months, 
discordant responders at 12 months experienced significantly more AIDS-defining events than 
full responders, with immunologic only responders presenting a slightly higher probability of 
being event-free compared to virologic only responders [25]. In another study involving over 
2,100 antiretroviral experienced and naïve HIV patients followed for a median of 44 months, 
immunologic only and virologic only responders had a significantly lower risk of clinical 
progression than non-responders, but a 2.3 and 1.9-fold greater risk of death or new AIDS-
defining event than complete responders, respectively [20].  
Little is known about the mechanisms underlying the development of discordant responses, 
but it apparently is dependent on the interaction of a multitude of viral and host factors. One 
hypothesis is that HAART selects viral strains that are less fit, which, in turn, results in reduced 
pathogenicity of drug resistant viruses. In fact, it has been shown that recipients of PI based 
regimens with prolonged discordance (immunologic success despite virological failure) have 
decreased viral replication capacity [45, 46, 51]. In one closely followed cohort of HAART naïve 
patients for whom repeated measures over a period of 1 year were analyzed, almost all patients 
who showed discordant immunologic response at 1 year had had either a prior transient period of 
undetectable plasma viral load and/or partial suppression of viral load to <1,000 copies/mL, 
 50
suggesting that partial viral suppression is the primary mechanism involved in discordant CD4 
cell count increases [44]. Genetic variability, such as polymorphisms associated with drug 
transportation [32] and T lymphocyte apoptosis [38, 39] has been implicated in the pathogenesis 
of virologic only response. In addition, the concomitant use of tenofovir and didanosine has been 
shown to cause impaired immunologic response [43, 101]. In ART-LINC the negligible 
proportion of patients initiating therapy with this combination is not likely to have influenced our 
results. 
A major strength of the present study is the large number of previously naïve patients 
starting therapy with NNRTI-based regimens. Most studies published so far have been conducted 
in developed countries and have included experienced patients receiving PI based regimens; 
these patients are not representative of patients starting therapy in resource limited settings, 
where the majority start treatment with NNRTI based regimens [58, 62].  
Our study has several limitations. First, this study did not address the impact of adherence 
on outcomes. In the study of Moore et al.[88], suboptimal adherence was predictive of both 
virologic and immunologic only responses rather than complete response. Second, additional 
variability may have been introduced due to differences in population genetics or infecting HIV 
subtypes, which were not considered in the present analysis. Third, patients prescribed NNRTI 
had lower plasma HIV-RNA levels and higher CD4 cell counts than patients prescribed PIs, 
highlighting the importance of provider bias determining differences between different regimens 
[102]. Four, we acknowledge that the 38% unknown response rate potentially could affect our 
results. However, our analysis showed that this group of patients did not differ significantly from 
the patients in the other categories of response with respect to major baseline risk factors. We 
believe that the availability of laboratory resources on site or other factors that limited access to 
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laboratory tests were determinants of this response pattern rather than patient characteristics. In 
addition, including patients with unknown response at 6 months did not substantially change the 
estimates in the final model. Finally, if the limited availability of resources caused programmes 
to prioritize monitoring virologic and immunologic responses in patients who did not appear to 
be doing well clinically, we could have underestimated the virologic and the immunologic 
effectiveness of HAART in these settings.  
Our results add to accumulating data on response to therapy in resource-limited countries, 
and may have important public health implications. We showed that despite considerable 
differences in disease severity at presentation and baseline CD4 count patients in resource-
limited settings, the frequency of and risk factors for discordant response are similar to those 
observed in developed countries. In these countries, higher mortality increasingly has been 
reported for discordant responders than for complete responders. Clinical management of these 
patients often requires both a more sophisticated laboratory approach (genotypic and phenotypic 
resistance) and the availability of a second line therapy. Data on the frequency of this 
phenomenon and identification of its risk factors are of capital importance and may help 
HIV/AIDS programmes plan their laboratory and therapeutic resources. Further studies are 
needed to assess the long-term impact of early discordant responses in these resource-limited 
countries. 
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4.0 ARTICLE 4 – EARLY IMMUNOLOGIC AND VIROLOGIC DISCORDANT 
RESPONSES AND MORTALITY IN PREVIOUSLY THERAPY-NAÏVE HIV-1 
INFECTED ADULTS INITIATING TREATMENT IN RESOURCE-CONSTRAINED 
COUNTRIES 
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4.1 ABSTRACT 
Objectives:  We assessed the impact of immunologic and virologic patterns of response at 6 
months of Highly Active Antiretroviral Therapy (HAART) in HIV-infected individuals from 
resource-limited countries. 
Methods: All previously naïve participants who initiated HAART between 1996 and 2007, were 
aged 16 years or older, had a known date of therapy initiation, and a documented baseline CD4 
were eligible for inclusion. Six (3 to 9) month response to therapy was categorized according to 
virologic, and immunologic responses considered jointly in: complete, virologic only, 
immunologic only; absent; and unknown response. Association between independent variables 
and outcomes were assessed by Cox proportional hazards regression. Robust standard errors 
were calculated to account for intra-site correlation. 
Results: A total of 11,380 patients were included in the analysis, and 386 deaths were reported 
during 19,295 person-years (PY), corresponding to a mortality rate of 2.00 (95% CI 1.81 – 2.21) 
per 100 PY. In multivariable analysis adjusted for age at HAART initiation, clinical stage, 
baseline CD4 cell count, history of an AIDS defining condition after the 6 month response, 
cohort, and year of HAART initiation, discordant immunologic and virologic responses and non-
responses were associated with increased risk of death. Compared with complete responders, 
virologic-only responders had a hazard of 2.29 (95% CI 1.64 – 3.20), immunologic-only 
responders had a HR of 2.22 (95% CI 1.52 – 3.26), and non-responders had a HR of 6.21 (95% 
CI 4.23 – 9.13).  
Conclusions:  Similar to what has been reported from developed countries, discordant 
immunologic and virologic responses were associated with intermediate risk of death in this 
large cohort of HIV-1 patients from resource-limited countries. 
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4.2 INTRODUCTION 
The initiation of HAART generally leads to a rapid reduction in HIV-1 RNA plasma levels and 
to an increase in peripheral CD4+ cell counts [5, 7, 8]. However, some patients experience a 
discordant response, whereby the HIV-1 RNA plasma level is below the limit of detection but 
the CD4+ cell count increase is blunted. Other patients exhibit a different pattern of discordant 
response, characterized by a sustained CD4+ cell count increase, despite persistent viremia. 
Published data have indicated that, in comparison to complete response, discordant responses are 
associated with an intermediate risk of death or clinical progression[20, 22, 25, 87].  
In the study of Grabar et al., virologic only responders and non-responders had a higher 
probability of clinical progression, whereas immunologic only responders and complete 
responders had similar risks [15]. In contrast, other studies have shown that immunologic only 
response also was associated with a higher risk of clinical progression. In one cohort of 
antiretroviral experienced patients with advanced HIV disease starting PI based HAART, that 
was followed for over 30 months, discordant responders at 12 months experienced significantly 
more AIDS-defining events than complete responders, with immunologic only responders 
having a slightly higher probability of being event-free compared to virologic only responders 
[25]. In another study involving over 2,100 antiretroviral experienced and naïve HIV patients 
followed for a median of 44 months, compared to complete responders, immunologic only and 
virologic only responders had significantly lower risk of clinical progression than non-
responders, but a 2.3 and 1.9-fold greater risks of death or of experiencing a new AIDS-defining 
event, respectively [20].  
Very few studies have assessed the prognostic value of discordant responses in naïve 
patients and in recipients of NNRTI-base regimens. In the study of Moore et al., mortality was 
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increased in patients showing an early discordant response, but no statistically significant 
difference was found between immunologic and virologic only responders [22]. Likewise, in a 
study involving HAART naïve IDU patients, discordant responders had an increased mortality 
compared to complete responders, but progression rates did not differ by whether early response 
was immunologic only or virologic only [90]. No published study has assessed the prognostic 
value of discordant responses in low-income countries. Our aim was to assess the association 
between immunovirologic discordant responses at 6 months of therapy and mortality in the 
ART-LINC collaboration.  
4.3 METHODS 
4.3.1 Study population  
The Antiretroviral in Lower Income Countries collaboration of the International Databases to 
Evaluate AIDS (ART-LINC of IeDEA) is a large collaborative network of HIV/AIDS treatment 
programmes in low and middle income countries in Africa, South America and Asia. The 
collaboration has been described in detail elsewhere [58, 62]. In brief, the collaboration was 
established in 2003 with the aim of characterizing the prognosis of HIV-infected patients treated 
with HAART in resource-limited settings, to compare the experience between different settings, 
delivery modes and types of monitoring; and to compare outcomes with those observed in 
industrialized nations. The data collected at participating sites are transferred to data 
management and statistical teams at the universities of Bern, Switzerland and Bordeaux, France 
where data are cleaned, merged and analyzed according to established protocols. The present 
analysis includes all data available up to 29 June 2007. All previously naïve participants in ART-
LINC who initiated HAART between 1996 and 2007, who were aged 16 years or older at 
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treatment initiation, had a known date of therapy initiation, and a documented baseline CD4 were 
eligible for inclusion. Only sites that collected HIV PVL routinely were included in the analysis. 
Patients who were missing both PVL and CD4 cell count at 6 (3 – 9) months were excluded. At 
all sites, local ethics committees or institutional review boards approved the collection of data.  
The following independent variables were assessed: age at therapy initiation (years); gender 
(female/male); site; stage of disease at HAART initiation, classified as less (CDC stage A/B, 
WHO stages I or II) or more advanced (CDC stage C, WHO stages III or IV); incidence of an 
opportunistic infection; baseline CD4 cell count (cells/μL); 6 (3 to 9) month response to therapy, 
according to virological (HIV PVL < 500 copies/mL), and immunological (increase of at least 50 
CD4 cells/μL) responses considered jointly, i.e., complete (VR+IR+), virologic only (VR+IR-), 
immunologic only (VR-IR+); absent (VR-IR-); and unknown response. First-line HAART 
regimens were categorized as NNRTI based (one NNRTI plus two NRTIs); PI based (one PI plus 
two NRTIs or ritonavir-boosted regimens); or other (including triple NRTI regimens and any 
other regimen containing a minimum of 3 drugs). Sites were categorized according to regions 
into Africa, Asia, and South America. 
4.3.2 Outcomes  
The endpoint was all cause mortality documented after a 6 (3 – 9) month response. Patients who 
died before the 6-month response were not included in the analysis. Time was measured from the 
6-month response and ended at the earliest of the date of death or last follow-up visit. A patient 
was considered lost to follow-up if the last visit was recorded during the first year after starting 
HAART and the patient had at least 1 year of additional potential follow-up until the closing date 
of the database. The closing date was defined for each cohort as the date of the most recent 
follow-up recorded in the database. Death was ascertained by local medical staff. 
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4.3.3 Statistical analysis 
Kaplan Meier curves were used to describe time from 6-month response to HAART to death, and 
log-rank tests were used to test the hypothesis of equality between survival functions. 
Associations between independent variables and mortality were assessed by Cox proportional 
hazards regression with complete responders serving as the reference group. Wald tests were 
used to test for differences between the two types of immunologic and virologic discordant 
responses, using linear contrasts of the coefficients. Hazard ratios (HRs) and 95% CIs are 
reported. Huber-White robust standard errors were calculated to account for intra-site 
correlation. The proportional hazards assumption was assessed graphically by plotting scaled 
Schoenfeld residuals against survival time for each factor separately, and by log-log survival 
plots for categories of immunologic and virologic response, adjusted for other covariates. 
Horizontal lines at zero in the former and parallel curves in the latter test are consistent with the 
proportional-hazards assumption.   
Preliminary analyses indicated that patients who had one measurement at 6 months (PVL or 
CD4 cell count) showed similar characteristics to patients who had both measurements at 6 
months. Therefore missing information on 6 month PVL or CD4 cell counts were imputed for 
those who had only one of these measurements, based on mortality status, loss to follow-up 
status, site, baseline CD4 cell count, sex, age and type of HAART regime. The occurrence of an 
incident AIDS defining event was modeled as a time dependent covariate. The ice command in 
Stata was used to multiply impute missing values [103].  In these imputations, values of the 
missing data were randomly sampled from their predicted distributions. Analyses were run on 
each of 5 datasets that included the imputed values, and the results combined with Rubin’s rules 
[95]. Analyses were performed using Stata version 9.0 (Stata Corp., College Station, TX). 
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4.4 RESULTS 
4.4.1 Study population 
A total of 20,015 antiretroviral-naïve participants from 14 sites, aged 16 years or older initiated 
HAART in the study period. Of these, 8,342 (41.7%) were excluded because they were missing 
both PVL and CD4 cell count measurements at 6 (3 - 9) months, and 293 (1.4%) were excluded 
because their last follow-up visit was the date of 6-month response. Compared to patients with 
both measurements at 6 months, individuals missing both 6-month measurements were more 
likely to be male, to have a lower CD4 cell count (median 99 vs. 106 cells/μL; p<.001), to be 
have an unknown clinical stage, and to be prescribed a non-standard HAART regimen. They also 
were more likely to be reported dead or lost to follow up. Compared to patients with both 
measurements at 6 months, individuals with one measurement were more likely to be male, to be 
older, to have higher baseline CD4 cell count and PVL, and to be prescribed a NNRTI-based 
regimen. They also were more likely to be reported to be lost to follow-up. Table 13 shows 
baseline characteristics and outcomes for 20,015 patients according to presence of a 6-month 
laboratory measurement. Kaplan-Meier survival curves are shown in Figure 2. The log-rank test 
for equality of survival functions showed no significant difference between the groups of patients 
who had one and both 6-month measures (p=.08), but a statistically significant difference 
between patients with both measurements vs. patients with neither measurement (p<.001). 
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Table 13. Patients’ baseline characteristics and outcomes according to the availability of a 6-
month measurement. 
Variable Total 
N = 20,015 
Both 
Measured 
N = 5,974 
1 Measured 
N = 5,708 
Neither 
Measured 
N = 8,342 
P value 
Both 
Measured 
vs. Neither 
Measured 
P value  
Both 
Measured 
vs. 1 
Measured 
Baseline characteristics       
Male gender n (%) 8,835 (44.1) 2,353 (39.4) 2,520 (44.2) 3,962 (47.5) <.001 <.001 
Age years (IQR) 35 (30 – 41) 34 (30 – 41) 35 (30 – 41) 35 (30 – 40) <97 <.001 
Baseline CD4 count 
cells/μL (IQR) 
106 (46 – 180) 106 (46 – 179) 116 (53 – 189) 99 (40 – 173) <.001 <.001 
Baseline PVL log10 
copies/mL (IQR) 
4.99  
(4.41 – 5.46) 
4.98  
(4.43 – 5.47) 
5.04  
(4.43 – 5.53) 
4.99  
(4.31 – 5.44) 
.07 .23 
Clinical stage n(%)     <.001 <.001 
Less advanced 1,699 (8.5) 722 (12.1) 563 (9.9) 414 (5.0)   
Advanced 16,545 (82.7) 4,853 (81.3) 4,630 (81.2) 7,062 (84.6)   
Unknown 1,771 (8.8) 394 (6.6) 511 (8.9) 866 (10.4)   
Regimen type n (%)     <.001 <.001 
NNRTI based 16,517 (82.5) 4,809 (80.6) 4,850 (85.0) 6,858 (82.2)   
PI based 2,069 (10.3) 864 (14.5) 429 (7.5) 776 (9.3)   
Other  1,429 (7.2) 296 (4.9) 425 (7.5) 708 (8.5)   
Outcomes       
Mortality rate per 100PY 
(95% CI) 
3.92  
(3.72 – 4.14) 
1.42  
(1.22 – 1.64) 
1.75  
(1.53 – 2.00) 
10.43  
(9.78 – 11.12) 
<.001 .08 
Loss to follow-up n (%) 3,095 (15.5) 569 (9.5) 662 (11.6) 1,864 (22.4) <.001 <.001 
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Figure 2. Kaplan-Meier survival curves according to availability of 6-month measurements 
For the subsequent analysis, we excluded patients with neither measurement at 6 months. Figure 
3 shows the disposition of patients included in the all-cause mortality analysis. 
Inclusion
Patients eligible for inclusion:
HIV-1 infected
>16 years of age
Previously therapy-naïveCD4 cell count measured at 
baseline
20,015 patients
Primary endpoint
11,380 patients
Exclusion
No laboratory measurement at 6 
months (n=8,342)
Follow-up ended before 6-month 
measurement (n=293)
Death
(n=386)
Lost to follow-up
(n=1,102)
No clinical event
(n=9,892)
 
 Figure 3. Patient disposition and outcomes  
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Of the 11,380 patients included in the present analysis, 4,739 (41.6%) were male, and the 
median age was 35 [interquartile range (IQR) 30 – 41)]. The median baseline CD4 cell count 
was 110 (IQR 49 – 184) cells/μL, and median PVL was 4.90 (IQR 4.25 – 5.50) log10 copies/mL. 
The majority of the patients (81.5%) was at advanced stage of disease and was prescribed a 
NNRTI-based regimen as first line therapy (82.7%). At 6 (3 – 9) months, 7,181 patients (63.1%) 
showed complete response; 1,710 (15.0%) had virologic-only response; 1,653 (14.5%) had 
immunologic-only response; and 836 (7.4%) showed no response. Baseline characteristics of the 
patients according to immunologic and virologic responses at 6 months are shown in Table 14. 
At baseline, virologic-only responders had the highest CD4 cell count and the lowest PVL, 
whereas immunologic-only responders had the lowest CD4 cell count and the highest PVL. 
Virologic-only responders tended to be older than patients from other categories of response.  
 
Table 14. Patients’ baseline characteristics and outcomes according to immunologic and 
virologic responses at 6 months of therapy. 
Variable Total 
N = 11,380 
VR+IR+ 
N = 7,181 
VR+IR- 
N = 1,710 
VR-IR+ 
N = 1,653 
VR-IR- 
N = 836 
Baseline characteristics      
Male gender n (%) 4,739 (41.7) 2,804 (39.0) 747 (43.7) 750 (45.4) 438 (52.4) 
Age years (IQR) 35 (30 – 41) 35 (30 – 41) 36 (31 – 43) 34 (29 – 40) 35 (30 – 41) 
Baseline CD4 count cells/μL 
(IQR) 
110  
(49 – 184) 
103  
(47 – 175) 
147  
(75 – 238) 
95  
(41 – 170) 
131  
(63 – 214) 
Baseline PVL log10 copies/mL 
(IQR) 
4.90  
(4.25 – 5.50) 
4.94  
(4.30 – 5.53) 
4.60  
(3.91 – 5.21) 
5.06  
(4.39 – 5.70) 
4.85  
(4.14 – 5.49) 
Clinical stage n(%)      
Less advanced 1,254 (11.0) 822 (11.4) 231 (13.5) 138 (8.4) 63 (7.5) 
Advanced 9,277 (81.5) 5,846 (81.4) 1,343 (78.5) 1,389 (84.0) 702 (84.0) 
Unknown 849 (7.5) 516 (7.2) 136 (8.0) 126 (7.6) 71 (8.5) 
Regimen type n (%)      
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Table 14 continued: 
 
Variable Total 
N = 11,380 
VR+IR+ 
N = 7,181 
VR+IR- 
N = 1,710 
VR-IR+ 
N = 1,653 
VR-IR- 
N = 836 
NNRTI based 9,410 (82.7) 6,266 (87.3) 1,453 (85.0) 1,164 (70.4) 527 (63.0) 
PI based 1,262 (11.1) 640 (8.9) 168 (9.8) 274 (16.6) 180 (21.5) 
Other  708 (6.2) 275 (3.8) 89 (5.2) 215 (13.0) 129 (15.4) 
Outcomes      
Mortality rate per 100PY 
(95% CI) 
2.00  
(1.81 – 2.21) 
1.31  
(1.12 – 1.54) 
3.03  
(2.43 – 3.78) 
2.02  
(1.60 – 2.54) 
4.98  
(4.03 – 6.16) 
Loss to follow-up n (%) 1,102 (9.7) 548 (7.6) 140 (8.2) 247 (14.9) 167 (20.0) 
  
4.4.2 All-cause mortality  
A total of 386 deaths were reported during 19,295 person-years (PY), corresponding to a 
mortality rate of 2.00 (95% CI 1.81 – 2.21) per 100 PY (Table 14). The mortality rate was 
highest among non-responders, followed by virologic-only, immunologic-only, and complete 
responders. The overall rate of loss-to-follow-up was 9.7%, and was highest among non-
responders (20.0%). Table 15 summarizes mortality rates and median follow-up times for each 
of the 14 participating sites, and the corresponding geographic regions. The mortality rates 
varied across sites, and were generally higher in Africa.  The median follow-up time was 1.15 
years (IQR 0.60 – 2.12), and varied across sites. The two Brazilian sites had the longest follow-
up times (median 4.03 [IQR 1.14 – 6.19]; and 4.25 [IQR 1.83 – 6.44] years for Rio de Janeiro 
and Porto Alegre, respectively). Figures 4, 5 and 6 show the Kaplan-Meier survival curves of 
participating cohorts by region.  
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Figure 4. Kaplan-Meier estimates of probability of survival of cohorts in Africa 
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Figure 5. Kaplan-Meier estimates of probability of survival of the cohort in Asia (India) 
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Figure 6. Kaplan-Meier estimates of probability of survival of cohorts in South America 
Table 15. Site-specific mortality and follow-up for the 14 participating ART-LINC sites 
Cohort Mortality  
rate per 100 PY (95%CI) 
Median follow up  
time in years (IQR) 
Loss to follow up  
rate (%) 
1290ANRS (Côte d’Ivoire) 7.14 (4.96 – 10.28) 1.48 (1.41 – 1.50) 55.8 
AMU (Uganda) 3.55 (1.33 – 9.46) 1.39 (0.99 – 1.90) 2.5 
CEPREF (Côte d’Ivoire) 2.55 (2.07 – 3.14) 1.68 (0.92 – 2.26) 2.7 
CONNAUGHT (Zimbabwe) 2.49 (1.57 – 3.96) 0.99 (0.57 – 1.68) 2.0 
GUGULETHU (South Africa) 3.26 (2.43 – 4.38) 0.92 (0.34 – 1.53) 2.0 
ISS (Uganda) 3.13 (0.44 – 22.21) 0.33 (0.15 – 1.30) 17.5 
KHAYELITSH (South Africa) 2.64 (2.00 – 3.49) 1.02 (0.55 – 1.67) 3.1 
MAROC (Morocco) 2.41 (1.47 – 3.93) 1.36 (0.79 – 3.41) 48.7 
PHRU (South Africa) 4.21 (2.39 – 7.42) 0.52 (0.38 – 0.69) 0.2 
PUMA (Argentina) 0.55 (0.07 – 3.91) 0.90 (0.52 – 1.28) 14.4 
RIOHIV (Brazil) 1.30 (0.86 – 1.98) 4.03 (1.14 – 6.19) 6.7 
SOBRHIV (Brazil) 1.02 (0.74 – 1.39) 4.25 (1.83 – 6.44) 18.2 
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Table 15 continued: 
 
Cohort Mortality  
rate per 100 PY (95%CI) 
Median follow up  
time in years (IQR) 
Loss to follow up  
rate (%) 
WITS (South Africa) 0.30 (0.11 – 0.82) 0.94 (0.63 – 1.14) 2.1 
YRGCARE (India) 1.70 (1.31 – 2.20) 1.43 (0.50 – 3.03) 21.7 
Region Mortality  
rate per 100 PY (95%CI) 
Median follow up  
time in years (IQR) 
Loss to follow up  
rate (%) 
Africa 2.61 (2.31 – 2.94) 1.04 (0.57 – 1.64) 6.2 
Asia (India) 1.70 (1.32 – 2.20) 1.43 (0.50 – 3.03) 21.7 
South America 1.09 (0.85 – 1.39) 3.50 (1.15 – 6.08) 14.4 
 
The Kaplan-Meier survival curves of categories of immunologic and virologic responses 
(complete, virologic only, immunologic only, and absent) are shown in Figure 4. The log-rank 
test for equality of survival functions showed significant differences between these groups 
(p<.001), with the complete responders having the best survival and the non-responders having 
the worst survival. Figures 5, 6 and 7 show the corresponding Kaplan-Meier survival curves for  
the 3 regions (Africa, Asia, and South America). These figures show the same general pattern for 
complete responders and non-responders across regions, with some inconsistent relationships 
between the two categories of discordant responses. Life tables with probability of remaining 
alive by a given time and corresponding 95% CI for each category combination of  immunologic 
and virologic responses are shown in the Appendix.  
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Figure 7. Kaplan-Meier estimates of probability of survival according to categories of 
immunologic and virologic responses at 6 months in 11, 380 patients.  
0.
50
0.
60
0.
70
0.
80
0.
90
1.
00
Pr
ob
ab
ilit
y 
of
 S
ur
vi
va
l
0 2 4 6 8
Analysis Time (years)
Complete Virologic-only
Immunologic-only Nonresponse
KM Curves by Categories Response in Africa
 
Figure 8. Kaplan-Meier estimates of probability of survival according to categories of 
immunologic and virologic responses at 6 months in Africa. 
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Figure 9. Kaplan-Meier estimates of probability of survival according to categories of 
immunologic and virologic responses at 6 months in Asia. 
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Figure 10. Kaplan-Meier estimates of probability of survival according to categories of 
immunologic and virologic responses at 6 months in South America. 
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In multivariable analysis adjusted for age at HAART initiation, clinical stage, baseline CD4 
cell count, history of an AIDS defining condition after the 6 month response, cohort, and year of 
HAART initiation, both categories of discordant immunologic and virologic responses and non-
responses were associated with increased risk of death. Compared with complete responders, 
virologic-only responders had a HR of 2.29 (95% CI 1.64 – 3.20), immunologic-only responders 
had a HR of 2.22 (95% CI 1.52 – 3.26), and non-responders had a HR of 6.21 (95% CI 4.23 – 
9.13). Age greater than 50 years was also associated with increased risk of death (HR compared 
to 16 – 29 year category: 1.74; 95% CI 1.27 – 2.38). A higher baseline CD4 cell count was 
independently associated with improved survival (HR for increase in 100 cells/μL 0.73; 95% CI 
0.65 – 0.83), even after adjusting for the 6 month response. Having an AIDS defining condition 
was associated with a hazard of 6.43 (95% CI 4.40 – 9.39). The two types of discordant 
immunologic and virologic responses were significantly different (Wald test p = .016). Plots of 
scaled Schoenfeld residuals for each variable included in the final model did not show violation 
of the proportional hazards assumption (Appendix). Results from univariate and multivariable 
analyses are summarized in Table 16.  
 
Table 16. Unadjusted and adjusted Cox proportional hazards and 95% confidence intervals of 
all-cause mortality for 11,380 patients* 
Variable Unadjusted HR P Adjusted HR P 
6-month response     
Complete (ref) 1.00  1.00  
Virologic-only 2.30 (1.65 – 3.19) <.001 2.29 (1.64 – 3.20) <.001 
Immunologic-only 1.71 (1.28 – 2.28) <.001 2.22 (1.52 – 3.26) <.001 
Absent 4.26 (2.94 – 6.16) <.001 6.21 (4.23 – 9.13) <.001 
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Table 16 continued: 
 
Variable Unadjusted HR P Adjusted HR P 
Baseline CD4 cell 
count (100cells 
increase/μL) 
0.78 (0.68 – 0.89) <.001 0.73 (0.65 – 0.83) <.001 
Age     
16 – 29 (ref) 1.00  1.00  
30 – 39 1.08 (0.88 – 1.33) .429 1.07 (0.85 – 1.35) .539 
40 – 49 1.19 (0.95 – 1.48) .124 1.12 (0.93 – 1.36) .233 
50+ 1.64 (1.28 – 2.09) <.001 1.74 (1.27 – 2.38) .001 
Clinical stage     
Less advanced (ref) 1.00  –  
Advanced 1.21 (0.80 – 1.83) .352 –  
Unknown 1.26 (0.81 – 1.98) .298 –  
AIDS defining event 6.73 (4.96 – 9.13) <.001 6.43 (4.40 – 9.39) <.001 
ARV Regimen     
NNRTI based (ref) 1.00  –  
PI-based  1.13 (0.78 – 1.63) .509 –  
Other 1.09 (0.65 – 1.84) .742 –  
*Adjusted for year of therapy initiation and site as fixed effects 
 
4.5 DISCUSSION 
We report on the impact of immunologic and virologic discordant responses at 6 months after 
HAART initiation in a large collaboration of cohorts from lower income countries. Our analysis 
showed that both types of discordant responses are associated with increased risk of death 
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relative to complete responders, which is in agreement with previous reports from developed 
countries [20, 22, 25]. 
Understanding the relationship between early responses to HAART and mortality has 
critical implications for guiding treatment modifications, particularly for those patients who 
show discordant immunologic and virologic responses. In resource-limited settings, where 
second- and third-line regimen options as well as access to laboratory tests often are limited, the 
additional problem of background morbidity may pose a challenge for developing treatment 
guidelines. We previously reported that incidence of discordant immunologic and virologic  
responses in resource-constrained countries were similar to that observed in resource-rich 
settings [104]. In this analysis, we assessed whether risk of death was increased in patients 
showing discordant immunologic and virologic responses at 6 months of HAART in the same 
population.  
Our results are similar to those reported by Moore et al.[22], who assessed the independent 
association of discordant responses with mortality in 2,217 ARV-naïve individuals initiating 
HAART in British Columbia. These authors also found that discordant responses were 
associated with increased risk of death when compared with complete responders. Our results are 
also in line with those of  Piketty et al., who reported that immunologic-only responders had a 
better outcome than virologic-only responders in a study involving 150 HIV-infected individuals 
[25].  
One concern that arises from the wide use of NNRTI-based regimens is that qualitative 
differences in immunologic-only response could exist between PI and NNRTI recipients due to 
different genetic barriers to resistance. One could hypothesize that lack of virologic suppression 
in the former group would be due to reduced viral fitness [45, 89], while in the latter group 
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would be due to genotypic resistance, which, in turn, could be associated with a worse outcome. 
A study of 1,138 previously antiretroviral therapy naive HIV-infected individuals from British 
Columbia showed that patients who developed resistance to NNRTI had a risk 3.02 times higher 
than those who had no resistance [105]. Although we did not find an association between 
regimen type and mortality in our analysis, direct comparisons of different regimens in 
observational studies are subject to selection bias. Further studies are needed to clarify the 
association of different patterns of immunologic-only response between recipients of PI vs non-
PI regimens, particularly with respect to the emergence of resistance. 
Of note, our analysis did not confirm the superiority of 6-month response over baseline 
values for predicting clinical progression or death, as studies from developed countries have 
previously demonstrated. In a large collaboration of cohorts from Europe and North America, 
baseline CD4 and HIV-1 RNA were not associated with disease progression or death after 
controlling for 6-month values [69], suggesting that even advanced immune suppression could 
be overcome with HAART. Similar findings are reported by Anastos et al. among HIV-infected 
women in the USA [18]. In ART-LINC, although 6-month values were predictive of death or 
clinical progression, baseline CD4 count remained a strong predictor in the final model. Indeed, 
it has been increasingly argued that the degree of initial immunologic damage has profound long-
term consequences. A study of patients who maintained sustained virologic suppression for up to 
6 years showed that although the initial CD4 cell gain is higher among those with lower baseline 
values, only patients with a baseline value of > 350 cells/μL had CD4 cell counts returned to 
nearly normal values at 6 years [106]. Studies from South [107] and West Africa [108] support 
the notion that, in these regions, HAART should be considered before CD4 cell count drops to 
levels <350 cells/μL, due to the high morbidity and mortality observed among these patients. It 
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appears that severe immunodepression, perhaps associated with other clinical conditions, is not 
overcome by HAART in resource-limited as it is in resource-rich settings, and that specific 
prognostic models need to be developed for resource-limited settings. 
Our study has several limitations. First, data on adherence were not available in our sample. 
Several studies have shown the independent association between poor adherence and increased 
mortality [22, 109, 110]. Second, other possible confounders could not be assessed in our study. 
For example, studies on the pathogenesis of immunologic-only response have suggested possible 
roles of factors associated with viral subtypes, such as non-syncytion-inducing (CCR5-tropic) 
viruses [46], reduced viral fitness [45], decreased T-cell activation [111, 112], and host-related 
determinants such as genetic polymorphisms [39]. Poor CD4 cell recovery has been associated 
with regimens containing didanosine plus tenofovir [99], and polymorphisms of interleukin-6 
and central major histocompatibility complex genes [38]. Third, the exclusion of nearly 40% of 
patients due to lack of information on the 6-month response potentially could have introduced a 
bias into our results. Excluded patients due to missing of 6-month response differed with respect 
to some baseline characteristics, were more likely to be lost to follow-up, and showed worse 
outcomes than those remaining in the analysis. Arguably, having at least one laboratory measure 
taken at 6 months is a marker of better compliance to service and, consequently, to treatment. 
Because we could not make any inferences about missing patterns of those who missed both 
types of response, we decided to exclude them from the analysis. Finally, we also noticed a 
tendency of higher loss to follow-up rate among non-responders. These patients also were more 
likely to die, so this finding could be indicative of a selection bias and could have led us to 
underestimate the hazard for this group. Therefore, our results can be generalized to patients 
from lower income countries who have a 6-month laboratory assessment.  
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In conclusion, we found in ART-LINC that both types of immunologic and virologic 
discordant responses were predictors of mortality when compared with complete responses. This 
is the largest study to date using pooled data from resource-limited countries, where most of 
naïve patients are initiating HAART with NNRTI-based regimens. Most studies published so far 
have been conducted in developed countries and have included patients using PI-based regimens. 
Our results suggest that, similar to resource-rich settings, both immunologic and virologic 
assessment are important for predicting mortality in patients receiving HAART in resource-
constrained countries, and provide a strong argument for recommending the wider availability of 
plasma viral load testing to guide therapy switch in these settings.  
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5.0 GENERAL DISCUSSION AND PUBLIC HEALTH IMPORTANCE 
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The global goal of reversing the picture of HIV epidemic by 2015, through radically scaling up 
prevention, treatment and care has required a substantial amount of funding to expand 
programmes and increase antiretroviral therapy coverage rates. Yet, nearly 5 million people still 
are in need of therapy, and the sustainability of scaling-up strategies remains questionable, as 
there is scarce evidence base to guide policy in low- and middle-income countries. Although 
available data on treatment are improving gradually, more extensive knowledge about treatment 
impact, toxicities, and drug resistance will be needed to guide the scale-up and allow 
sustainability of treatment programmes.  
Several factors that are particular to the countries where AIDS has struck most heavily, such 
as high prevalence of background infectious diseases, structural and cultural barriers, and even 
population and virus genetic patterns potentially could affect the effectiveness of HAART. Thus, 
prognostic models and treatment guidelines that are based on data from resource-rich settings 
likely are not suitable for guiding public health strategies in resource-limited settings. Initiatives 
such as ART-LINC and IeDEA are of capital importance to provide answers and insights on this 
issue. Here we presented four papers that assess the effectiveness of HAART using data from 
ART-LINC. 
The first paper is a literature review of immunologic and virologic discordant reponses to 
antiretroviral therapy. Although there is a growing interest on the issue, the lack of a universal 
definition for discordance makes it difficult to establish meaningful comparisons between 
studies. The second paper assessed the effectiveness of HAART – measured as a virologic 
suppression after 6 months on therapy, in a Brazilian cohort – and found it to be similar to 
developed countries. We also showed that response rates improved over time, which could be 
attributed to the introduction of more potent antiretroviral drugs that also allowed a better 
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adherence. The Brazilian experience has been seen as a model for understanding many aspects of 
the HIV epidemic in resource-constrained settings and provided important lessons for other 
developing countries that aim to provide universal access to HAART. However, Brazil now 
faces the challenge of sustaining the policy of universal access to antiretrovirals as the number of 
patients on treatment is increasing and so is the need for more complex and costly regimens 
[113, 114]. Nevertheless, Brazil’s AIDS treatment model resulted in sustained lower prices, 
saving Brazil over US$1 billion from 2001 to 2005 [115].  
In the third and fourth papers, we sought to assess the additional prognostic value of 
immunologic response in predicting clinical progression in ART-LINC. We first assessed the 
prevalence of and risk factors for immunologic and virologic responses (categorized as complete, 
virologic-only, immunologic-only, and absent), and found that they were similar to those 
reported in studies from resource-rich countries. We have found that, compared to complete 
responders, virologic only responders were older, had higher baseline CD4 counts, lower 
baseline viral load, and were more likely to have received a nonstandard HAART regimen; and 
immunologic only responders were younger, had a lower baseline CD4 count, and were more 
likely to have received a PI based or a nonstandard regimen. Higher baseline CD4 count was 
associated with an increased probability of a virologic only response and with a reduced 
probability of an immunologic only response [20, 88, 98]. One possible explanation for this 
finding is the non-linear nature of CD4 cell increase after HAART initiation across the different 
baseline CD4 count strata. In addition, the definition of immunologic response in this and other 
studies (increase in CD4 cell count by 50 cells) may be subject to a regression towards the mean 
effect, by which those at the highest baseline values would be less likely to show improvement 
than those with low baseline values  [116]. The fourth paper showed that both types of 
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discordant responses predict of clinical progression and mortality. However, we noticed a high 
proportion of patients who did not have a 6-month PVL and CD4 cell count measurement. This 
group of patients also had higher mortality and loss-to-follow-up rate, which led us to 
hypothesize that not having at least one measurement at 6 months of therapy was an indirect 
marker for less access to care and for other factors associated with worse outcome. The crude 
mortality rates for each of the four categories of immunologic and virologic response were also 
lower than the reported in the literature and are suggestive of a survival bias. This hypothesis is 
supported by another analysis done in this population, where cohorts with active tracing of 
patients showed a higher mortality than cohorts that had a passive follow-up system [58], 
suggesting that death is under ascertained in many cohorts participating in ART-LINC. In 
addition, ART-LINC sites may overrepresent ‘centres of excellence’, as eligibility criteria for 
participating in the collaboration include having electronic data collection capabilities. Lack of a 
minimal infrastructure to reliably record information on outcomes as well as high rates of loss to 
follow up are major obstacles to the conduct of high-impact research in these settings. 
In summary, we have demonstrated that effectiveness of HAART in low- and middle-
income countries is similar to that observed in resource-rich countries, provided that access to 
care is comparable. We also found differences between resource-limited and -rich countries and 
across ART-LINC sites that warrant additional research. Public health decisions about treatment 
guidelines must be driven by sound evidence of health effects, but still have to be weighted by 
aspects such as feasibility and contextual factors. Statistical models accounting for the 
hierarchical structure of individual and contextual factors are needed to better understand the 
potential impact of these factors, and will help develop prognostic models and treatment 
guidelines applicable to this setting.  
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APPENDICES 
APPENDIX A. Life-table, and survival probability plots with 95% confidence intervals for 
complete responders 
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Interval 
(years) 
Total at the 
beginning 
Events Persons 
at risk 
Probability 
of death 
95%CI 
0 – 1 7181 97 3024 0.9829 0.9792 0.986 
1 – 2 4060 26 2200 0.9743 0.9691 0.9786 
2 – 3 1834 12 908 0.9658 0.9584 0.9719 
3 – 4 914 4 363 0.9605 0.9512 0.9681 
4 – 5 547 6 203 0.9476 0.9326 0.9593 
5 – 6 338 2 133 0.9406 0.922 0.9549 
6 – 7 203 2 105 0.9281 0.9005 0.9483 
7 – 8 96 0 55 0.9281 0.9005 0.9483 
8 – 9 41 1 34 0.8894 0.7814 0.9458 
9 – 10 6 0 6 0.8894 0.7814 0.9458 
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APPENDIX B. Life-table, and survival probability plots with 95% confidence intervals for 
virologic-only responders 
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Interval 
(years) 
Total at the 
beginning 
Events Persons at 
risk 
Probability of 
death 
95%CI 
0 – 1 1710 57 777 0.95 0.94 0.96 
1 – 2 876 10 481 0.94 0.92 0.95 
2 – 3 385 6 165 0.92 0.90 0.94 
3 – 4 214 2 87 0.91 0.88 0.93 
4 – 5 125 3 38 0.88 0.84 0.91 
5 – 6 84 0 27 0.88 0.84 0.91 
6 – 7 57 0 27 0.88 0.84 0.91 
7 – 8 30 0 17 0.88 0.84 0.91 
8 – 9 13 0 9 0.88 0.84 0.91 
9 – 10 4 0 4 0.88 0.84 0.91 
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APPENDIX C. Life-table and survival probability plots with 95% confidence intervals for 
immunologic-only responders 
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Interval 
(years) 
Total at the 
beginning 
Events Persons 
at risk 
Probability of death 95%CI 
0 – 1 1653 29 539 0.97 0.97 0.98 
1 – 2 1085 13 464 0.96 0.95 0.97 
2 – 3 608 12 229 0.94 0.92 0.95 
3 – 4 367 6 74 0.92 0.89 0.94 
4 – 5 287 6 67 0.90 0.87 0.92 
5 – 6 214 2 58 0.89 0.85 0.91 
6 – 7 154 5 56 0.85 0.80 0.89 
7 – 8 93 0 47 0.85 0.80 0.89 
8 – 9 46 0 38 0.85 0.80 0.89 
9 – 10 8 0 8 0.85 0.80 0.89 
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APPENDIX D. Life-table and survival probability plots with 95% confidence intervals for 
nonresponders 
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Interval 
(years) 
Total at the 
beginning 
Events Persons at 
risk 
Probability 
of death 
95%CI 
0 – 1 836 57 311 0.92 0.89 0.93 
1 – 2 468 16 188 0.88 0.85 0.90 
2 – 3 264 4 90 0.86 0.83 0.89 
3 – 4 170 1 30 0.86 0.82 0.89 
4 – 5 139 6 23 0.82 0.77 0.86 
5 – 6 110 1 25 0.81 0.75 0.85 
6 – 7 84 0 25 0.81 0.75 0.85 
7 – 8 59 0 27 0.81 0.75 0.85 
8 – 9 32 0 25 0.81 0.75 0.85 
9 – 10 7 0 7 0.81 0.75 0.85 
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APPENDIX E. Plots of scaled Schoenfeld residuals for variables included in the final model  
a) Categories of immunologic and virologic responses 
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b) Baseline CD4 cell count (100 cells increase) 
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c) AIDS defining event 
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APPENDIX F. Log-log survival plots for categories of immunologic and virologic responses, 
adjusted for age, baseline CD4 count, site and AIDS defining events. 
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